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ABSTRACT
REGULATION OF GABA RELEASE BY PRESYNAPTIC CAV2.2 IN THE
BASOLATERAL AMYGDALA AND INFRALIMBIC CORTEX
by
Maxwell Robert Blazon
University of New Hampshire, May, 2018

Anxiety is linked to dysregulation of neuronal activity in several brain regions including
the infralimbic (IL) area of the medial prefrontal cortex (mPFC) and the basolateral nucleus of the
amygdala (BLA). Disruptions to the balance of excitatory and inhibitory signaling in these regions
are implicated in anxiety-like behaviors in animals and anxiety disorders in humans. The neuronal
circuitry between excitatory neurons, known as pyramidal cells (P-cells), and inhibitory neurons,
known as interneurons (INs), is a primary target for anxiety modulation at the cellular level. INs,
particularly the subtype that contain the neuropeptide cholecystokinin (CCK+INs), form inhibitory
synapses around P-cells. Through GABAergic neurotransmitter release, CCK+INs regulate P-cell
activity and subsequent anxiety-related neuronal output. Two protein complexes, the N-type
calcium channel (CaV2.2) and the type-1 cannabinoid receptor (CB1), are expressed in the
presynaptic terminal of CCK+INs. CaV2.2 and CB1 have been shown to regulate neurotransmitter
release from CCK+INs in the hippocampus, but it is not known if this role is conserved in the
anxiety-related neuronal circuits of the BLA and IL. CaV2.2 has also been shown to regulate the
intrinsic firing properties of P-cells in the hippocampus and deep cerebellar nuclei, but this role
has not been assessed in the IL. To investigate these neuronal circuits, I used a combination of
transgenic mouse models, confocal microscopy, patch-clamp electrophysiology, optogenetics, and
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pharmacology. In the first chapter of my thesis, I investigated the role of CaV2.2 in CCK+IN/Pcell synapses in the BLA. In the second chapter of my thesis, I investigated the role of CB1 in
regulating GABA release from CCK+INs in the BLA. In the third chapter of my thesis, I assessed
the regulation of GABA release and intrinsic firing by CaV2.2 in the IL. I present electrophysiology
data which demonstrate GABA release from CCK+INs is partially CaV2.2-dependent in the BLA.
I obtained preliminary electrophysiology recordings which suggest CB1 receptors modulate GABA
release in CCK+IN/P-cell synapses in the BLA. I found that neurotransmitter release from
GABAergic INs is partially CaV2.2-dependent in the IL. However, I found that GABA release
from CCK+INs is not CaV2.2-dependent in this region. Lastly, I observed that CaV2.2 plays a
minimal role in the intrinsic firing properties of P-cells in the IL. My findings suggest that CaV2.2
differentially regulates GABA release and intrinsic firing properties across brain regions,
suggesting there are region-specific implications of CaV2.2 modulation in anxiety-related neuronal
output.
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INTRODUCTION
Overview
Fear and anxiety are normal experiences in day-to-day life. Fear often results from an
apparent external danger, while anxiety is a widespread response to an unknown or non-specific
threat. Both trigger appropriate and adaptive responses to risks, be they physical, mental, or
societal (Steimer, 2002). When fear and anxiety become pathological, they can manifest as an
anxiety disorder. Anxiety disorders include panic disorder, generalized anxiety disorder,
agoraphobia, specific phobias, social anxiety disorder, post-traumatic stress disorder, obsessivecompulsive disorder, and separation anxiety disorder. In these conditions, an individual’s ability
to cope with various stressors is compromised, meaning non-threatening stimuli can cause severe
distress. Anxiety disorders alter numerous physiological processes, facilitating poor physical
health outcomes over time (Kroenke, Spitzer, Williams, Monahan, & Löwe, 2007). The National
Institute of Mental Health reports a 19.1% past-year prevalence of anxiety disorders in U.S. adults
(Harvard Medical School National Comorbidity Survey, 2017). Current medications used to treat
anxiety disorders (benzodiazepines, selective serotonin reuptake inhibitors) cause several adverse
effects (impaired cognition, addiction), thus many patients withdraw from treatment (Baldwin,
Woods, Lawson, & Taylor, 2011). A greater understanding of the neurobiology behind anxiety
disorders is required to produce more effective treatments.
Anxiety is a highly integrated emotional component of cognitive processing facilitated by
the thalamus, locus coeruleus, hypothalamus, hippocampus, amygdalar nuclei, and the prefrontal,
sensory, entorhinal, and association cortices (Steimer, 2002). Classically, these brain areas are
defined as components of the limbic system or ‘emotional brain.’ In animal models, their
connections are implicated in emotional learning and conduct, including fear-conditioning and
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anxiety-like behaviors (Steimer, 2002). Of particular importance for their role in modulating
anxiety are the medial prefrontal cortex (mPFC) and the basolateral amygdala (BLA). The mPFC
processes the cognitive components of anxiety (i.e. rumination) and mediates sympathetic nervous
system responses (fight-or-flight). The behavioral responses related to anxiety (i.e. avoidance) are
modulated by the BLA (Johansen, Cain, Ostroff, & Ledoux, 2011). While each area has
independent roles in anxiety, their interconnections are involved in fear expression and the
extinction of conditioned fear (Ferreira, Yousuf, Dalton, & Sheets, 2015; Milad & Quirk, 2002;
Phelps, Delgado, Nearing, & Ledoux, 2004). Research targeting the neural circuits involved in this
disruption may provide insight as to how anxiety is regulated at the cellular level.
The balance between excitatory and inhibitory activity in the mPFC and BLA is disrupted
in anxiety disorders (Ehrlich et al., 2009). Pyramidal neurons (P-cells) are the primary excitatory
cell type in the mPFC and BLA. P-cells receive excitatory inputs through projections from other
brain areas and inhibitory inputs from local interneurons (INs) (Freund, 2003). Multiple types of
INs exist, and the cholecystokinin-containing subtype (CCK+INs) are strongly linked to anxietyrelated behaviors (Truitt, Johnson, Dietrich, Fitz, & Shekhar, 2009). The inhibitory
neurotransmitter gamma-aminobutyric acid (GABA) is released from CCK+INs onto P-cells,
decreasing their excitability (Freund & Katona, 2007). Membrane proteins like voltage-gated
calcium channels (CaVs) and cannabinoid receptors modulate neurotransmitter release (Guo &
Ikeda, 2004). CaVs permit calcium ions to enter the presynaptic terminal which facilitate vesicular
fusion and neurotransmitter exocytosis. Cannabinoid receptors are coupled to CaVs and
downregulate calcium ion entry when activated by cannabinoids (Zamponi & Currie, 2013).
Additionally, CaVs modulate the intrinsic firing properties of P-cells by coupling to calciumactivated potassium channels (Loane, Lima, & Marrion, 2007). There are multiple CaV and
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cannabinoid receptor subtypes; the N-type calcium channel (CaV2.2) and the type-1 cannabinoid
receptor (CB1) are known to regulate neurotransmitter release from CCK+INs in the hippocampus
(Szabo et al., 2014). However, the role of CaV2.2 and CB1 in CCK+INs of the BLA and mPFC has
not been described. In my master’s thesis, I aim to elucidate the role of CaV2.2 in CCK+IN/P-cell
synapses in the BLA (CHAPTER 1) and determine if CB1 regulates neurotransmitter release in
this system (CHAPTER 2). Additionally, I will assess the role of CaV2.2 in regulating GABA
release and intrinsic firing properties in the infralimbic region of the mPFC (CHAPTER 3).

The Role of Fear and Anxiety in Survival
Emotions are thought to be the result of natural selection, as they prompt behavioral
responses important for survival (Darwin, 1998). A critical emotion for survival, fear, is defined
as a motivational state that promotes either defensive or escaping behaviors (Gherardi, McFarland,
& Tinbergen, 1988). Exposure to fearful stimuli often correlates with learning. Animals (including
humans) adapt behavioral changes to avoid repeat exposure to fear, particularly if the fearful
stimuli are associated with pain or stress. Fear-related learning can manifest through a closely
related emotion; anxiety (Steimer, 2002). Anxiety involves behavioral and physiological responses
including avoidance, vigilance, and arousal, all intended to protect the animal from danger. While
fear is focused on known dangerous stimuli, anxiety is often a directionless response to an
unknown danger or internal conflict (Ritu, Sandeep, Mamta, & Nirja, 2013).

Fear and Anxiety are Related to the Limbic System
The limbic system, also known as the ‘emotional brain,’ was largely defined by James
Papez (1937) and Paul MacLean (1955). Papez related brain areas like the cingulate cortex,
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thalamus, hypothalamus, hippocampus, and with emotional patterns observed in human
experiments. MacLean refined Papez’s work, highlighting the role of the prefrontal cortex and
subcortical areas like the amygdala and septum in emotional experiences (J. LeDoux, 1996; Roxo,
Franceschini, Zubaran, Kleber, & Sander, 2011). More than a series of brain structures, limbic
areas form a functional system. Feelings of fear and anxiety are complex, involving more than just
emotional components. For example, fear and/or anxiety-related stimuli are processed by the
prefrontal cortex (PFC), which modulates physiological and behavioral responses (via the
amygdala). The amygdala assimilates sensory, contextual, and cognitive information to influence
fear extinction, anxiety-related behavior, and selective attention (J. E. LeDoux, 2009; Steimer,
2002). The integration of cognitive, physiological, and sensory information in the BLA and PFC
illustrates the complexity of fear and anxiety (J. E. LeDoux, 2009).

The Role of the Medial Prefrontal Cortex in Anxiety
The PFC is believed to influence the conscious experiences and thoughts related to anxiety
(J. LeDoux, 1996; Steimer, 2002) as well as module anxiety-like behaviors (Sierra-Mercado,
Padilla-Coreano, & Quirk, 2011). fMRI studies show changes in PFC activity in patients with
anxiety disorders (generalized and post-traumatic), which are behaviorally characterized by the
inability to control fear responses (Sierra-Mercado et al., 2011). Deficient recruitment of the PFC
(ventromedial region) during fear inhibition is observed in patients with generalized anxiety
disorder (Greenberg, Carlson, Cha, Hajcak, & Mujica-Parodi, 2013). Similarly, decreased
activation of the PFC (ventromedial region) in response to trauma-related cues is present in
patients with post-traumatic stress disorder (PTSD) (Shin et al., 2004). In animal research, similar
observations have been made. Lesions to the rat PFC (right infralimbic region) were shown to have
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anxiolytic effects and suppress autonomic nervous system responses (Sullivan & Gratton, 2002).
In mouse models, the PFC is associated with fear-related learning and fear expression, both of
which can be impaired with selective inactivation of PFC sub-regions (Sierra-Mercado, Corcoran,
Lebrón-Milad, & Quirk, 2006; Sierra-Mercado et al., 2011)
The rodent PFC is comprised of multiple sub-regions with specialized functions including
the medial, lateral, and orbitofrontal cortices. The medial prefrontal cortex (mPFC) is the target of
extensive anxiety research (Duvarci & Pare, 2014; Morgan, Romanski, & LeDoux, 1993; Sullivan
& Gratton, 2002). Further divided, the mPFC is comprised into the anterior cingulate cortex (AC),
the prelimbic cortex (PL), and the infralimic cortex (IL) (Figure 1) (Paxinos & Watson, 2007).
The IL and PL play unique roles in anxiety-related processing and differentially connect to the
amygdala. The IL facilitates the storage of extinction learning in target structures (Do-Monte,
Manzano-Nieves, Quinones-Laracuente, Ramos-Medina, & Quirk, 2015). IL-BLA connections
are involved in the extinction of
conditioned fear (Ferreira et al.,
2015; Sierra-Mercado et al., 2011).
Excitatory neurons in the PL project
to the BLA and are involved in the
expression of fear (Sierra-Mercado
et al., 2011; Wang et al., 2015). In
rodents, fear is expressed by
Figure 1| Regions of the mouse medial prefrontal cortex. A

behaviors like freezing. An animal Nissl stained coronal section of the mouse brain containing the
PFC is paired with a stereotaxic atlas depiction of the subdivisions

that displays reduced explorative of the mPFC. AC, anterior cingulate; PL, prelimbic; IL,
infralimbic. Adapted from Michelsen et al., 2007; Paxinos &

behaviors or excessive grooming is Watson, 1998; Allen Mouse Brain Atlas.
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considered to be exhibiting anxiety-like behavior. Stressful stimuli activate the PL and increase
fear expression and anxiety-like behaviors (Hurley, Herbert, Moga, & Saper, 1991; Sullivan &
Gratton, 2002), while selective inactivation of the PL reduces them (Sierra-Mercado et al., 2011).
Abnormal activity in the connections from the PL and IL to the BLA can prompt inappropriate or
deficient response to fear (Greenberg et al., 2013), a characteristic common to anxiety disorders.

The Role of the Amygdala in Processing Fear and Anxiety
The amygdala is an almond-shaped, highly interconnected limbic system structure
implicated in the behavioral output of anxiety. Amygdalar functions and connections are conserved
across many species, suggesting that research findings in animal models like the mouse (Mus
musculus) may have human implications (Janak & Tye, 2015). For non-human primates, lesions
to the amygdala impair their ability to associate a stimulus with positive/non-harmful or
negative/potentially harmful outcomes (Weiskrantz, 1956) and lead to hypo-emotionality
(Aggleton & Passingham, 1981). In rodents, the amygdala facilitates behavioral responses (i.e.
freezing/playing dead in front of predator) by integrating rapid sensory input (i.e. visualization of
a predator) from the thalamus and slower sensory input (i.e. motivation to escape the predator)
from the prefrontal cortex (Steimer, 2002). Furthermore, the amygdala influences cognition,
perception, and associative learning (J. E. LeDoux, 2009; Steimer, 2002). In associative learning,
an animal relates a new response to a particular stimulus, or one stimulus to a second stimulus
(Janak & Tye, 2015). In humans, (Anderson & Phelps, 2001) and rats (Blanchard & Blanchard,
1972), damage to the amygdala hinders the ability to recognize fearful stimuli. Amygdalar
dysfunction is also caused by disruptions in the balance of excitatory and inhibitory signaling.
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These disruptions are observable in anxiety disorders (Etkin, Prater, Schatzberg, Menon, &
Greicius, 2009).
The amygdala is composed of several nuclei, including the basolateral amygdala (BLA)
and the central amygdala (CeA) (Figure 2). The BLA is further comprised of the basal amygdala
(BA) and lateral amygdala (LA), and is the main source of excitatory output to other brain regions
involved in fear and anxiety. Thalamic and cortical sensory signals project to the LA, which
connects to the BA and CeA (Keifer, Hurt, Ressler, & Marvar, 2015). Direct stimulation of the
BLA is correlated with anxiety-like behavior (Johansen et al., 2010). The BLA can both upregulate
and downregulate freezing behaviors through projections to the PL and IL, respectively, and is
involved in anxiety-related memories via hippocampal connections (Sierra-Mercado et al., 2011).
Opposite of the BLA, the CeA is mainly composed of inhibitory interneurons. Divided into the
centromedial

(CEm)

and

centrolateral amygdala (CEl),
the CeA is involved in the
translation of BLA signals to
behavioral output (Janak & Tye,
2015). It has been demonstrated
that inhibition of BLA-CeA
connections increases anxiety-

Figure 2| Regions of the mouse amygdala. A Nissl stained coronal
section of the mouse brain is paired with a diagram representing the
related behaviors while direct amygdala nuclei. The basal (BA) and lateral (LA) nuclei comprise the
basolateral amygdala (BLA) while the centromedial (CEm) and
stimulation decreases them (Tye centrolateral (CEl) nuclei comprise the central amygdala (CeA).
Adapted from Allen Mouse Brain Atlas; Keifer et al., 2015.

et al., 2011).
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The Role of the Hippocampus in Anxiety-related Learning and Memory
The HPC is divided into ventral and dorsal regions, each of which contains Cornu
Ammonis (CA) regions (CA1 - CA4). Additionally, the CA regions contain a system of laminar
organization (Figure 3). The stratum oriens (SO), stratum pyramidale (SP), stratum radiatum (SR),
and stratum lacunosum-moleculare (slm) possess different cells, circuit organization, and functions
in hippocampal processes. The ventral portion of the hippocampus (vHPC) is implicated in fear
conditioning and anxiety-like behavior through its connections with the mPFC and BLA. BLAvHPC connections are necessary for forming memories of environmental context (Goosens, 2001;
Maren & Fanselow, 1995), while vHPC-mPFC connections are required for retrieving memories
when presented with specific context (Sierra-Mercado et al., 2011). Contextual memory and the
memory retrieval process are important for the survival of a species, especially when the context
involves perceived danger or negative emotions (Goosens, 2001). Chronic stress, fear, and anxiety

Figure 3| Regions of the mouse hippocampus. A Nissl stained coronal section of the mouse brain
is paired with a diagram detailing the regions and layers of the vHPC. CA, Cornu Ammonis; so,
stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; slm, stratum lacunosum-moleculare.
Adapted from Allen Mouse Brain Atlas; Silva-Gómez, 2013; Paxinos & Watson, 1998.
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can disrupt these processes and result in a state of hippocampal dysfunction. There is evidence that
hippocampal dysfunction is both a risk factor for developing and complication of anxiety disorders
(Cominski, Jiao, Catuzzi, Stewart, & Pang, 2014).

Cells and Circuits in Anxiety-related Brain Areas
New and developing pharmacological treatments for anxiety disorders must aim to
decrease activity in the neural circuits that influence anxiety and increase activity in those that
reduce anxiety. Fundamental to these objectives is research which provides a more complete
understanding of the molecular neuroanatomy of the limbic system and the functional
neurophysiology of anxiety disorders. Communication between and within limbic system areas is
facilitated by complex and highly organized neuronal circuits. Similar cell types and circuitry are
thought to exist across limbic regions like the mPFC, BLA, and vHPC (Jinno, 2009). However, it
is not understood if there are underlying functional differences in these circuits, nor what
implications they might have in the neuronal processes of anxiety.
The mPFC, BLA, and vHPC contain a mixture of excitatory (glutamatergic) pyramidal
cells (P-cells) and inhibitory (GABAergic) interneurons (INs). P-cells are characterized by their
piriform morphology, apical dendrites, and long axons which allow for communication across
brain regions. INs innervate local P-cells and are classified by the domain in which they target.
INs that target P-cell bodies (somas/somatas) are termed basket cells (BCs), those that target the
axon initial segments are termed chandelier cells, and those that target dendrites are termed
dendritic inhibitory cells (Freund, 2003). INs can be further categorized by identifying their
intrinsic firing properties and neuropeptide content. Intrinsic firing properties, including action
potential spike frequency and firing pattern, indicate how an IN behaves in a neuronal circuit
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(Benda & Herz, 2003). Neuropeptide contents are used as a marker of IN subtypes, and indicate
the neurotransmitters, receptors, and functions likely associated with a particular subtype. In the
mPFC, BLA, and HPC, several subtypes of BCs have been identified for their unique roles in
influencing P-cell activity (Barsy, Szabó, Andrási, Vikór, & Hájos, 2017; Freund, 2003; Whissell,
Cajanding, Fogel, & Kim, 2015). BCs containing the neuropeptide parvalbumin (PV+BCs)
process multiple converging stimuli and display fast, non-adapting firing patterns (Nyíri,
Stephenson, Freund, & Somogyi, 2003). Cholecystokinin-containing BCs (CCK+BCs) respond to
slow, asynchronous inputs and display moderate, adapting firing patterns (Bartos & Elgueta, 2012;
Veres, Nagy, & Hájos, 2017). Understanding functional specifics about INs within limbic
structures may help elucidate their complex role in mediating fear and anxiety.
Descriptions of the wiring, innervation, and postsynaptic targets of INs requires a
description of how IN/P-cell networks operate. Across P-cells and IN subtypes, there are variations
in intrinsic firing and synaptic properties (Kullmann, 2011). In general, the synaptic events which
excite INs are faster than those that excite P-cells. This is advantageous for controlling anxiogenic
pathways, as excitation is under strict regulation by INs, particularly BCs (Deleuze, Pazienti, &
Bacci, 2014). This regulation comes in multiple forms including feedforward inhibition. In
feedforward inhibition, a local IN, excited by an afferent projection, delivers an inhibitory signal
to a P-cell. Depending on the cellular properties of the IN, feedforward inhibition can limit the
window for action potential generation or cancel out P-cell excitation (Jasnow, Ressler, Hammack,
Chhatwal, & Rainnie, 2009). In addition to feedforward inhibition, there is feedback inhibition.
The firing of P-cells activates INs, which in turn inhibit P-cells (Freund & Katona, 2007). Once
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feedback and feedforward inhibition decline,
P-cells are able to fire again. The combination
of

feedforward

and

feedback

inhibition

establish a neuronal oscillation, also known as
a brainwave (Möhler, 2002). A prominent form
of inhibition in the BLA and mPFC is known as
perisomatic inhibition (Figure 4), wherein
CCK+BCs and PV+BCs synchronize the

Figure 4| Perisomatic inhibition. Simplified circuit
activity of local P-cells (Freund & Katona, diagram depicting perisomatic inhibition of a
pyramidal cell by parvalbumin (PV+) and
cholecystokinin (CCK+) containing basket cell
2007). The synapses made in perisomatic interneurons (INs). Adapted from Deleuze et al.,
2014.

inhibitory are highly modifiable by ion

channels, neurotransmitters, and additional extracellular messengers, prompting a closer review of
their underlying molecular components of in anxiety-implicated circuits of the vHPC, mPFC, and
BLA.
In the vHPC, excitatory signaling is transmitted through P-cell projections from CA3 to
CA1. Anxiety research often targets CA3 and CA1, as these sub-regions are major output pathways
to other limbic areas. Several networks of INs exist within these output pathways which can
modulate P-cell activity (Kullmann, 2011). These include fast-spiking PV+BCs, regular-spiking
CCK+BCs, chandelier INs, and Schaffer collateral-associated (SCA) INs (Kullmann, 2011).
Research has shown that while PV+BCs are more abundant overall, CCK+BCs outnumber
PV+BCs in several sub-regions of the hippocampus (Whissell et al., 2015). The most superior
layer of the vHPC, the SO, contains BC bodies and the basal dendrites of P-cells, whose cell bodies
are located the second-most superior layer, the SP (Lacaille & Williams, 1990). The SP is
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recognizable by its dense P-cell composition and role in hippocampal output. BCs can be found in
the SP as well; their proximity to P-cells illustrates their known role in perisomatic inhibition (Neu,
Földy, & Soltesz, 2007; Whissell et al., 2015). The layer immediately following the SP, the SR,
contains P-cell projections from CA3 to CA1, termed the Schaffer collaterals. Schaffer collaterals
are the topic of extensive neuropsychiatric research, as they are critical for long-term potentiation
and emotional memory (Kumar, 2011; Stanton, Winterer, Zhang, & Müller, 2005). BCs in CA1
are innervated by Schaffer collaterals, while the dendrites of Schaffer collaterals themselves are
innervated by SCA INs (Kullmann, 2011).
Similar to the SP layer of the vHPC, the mPFC contains mostly P-cells (80-90%) with a
minority of INs (10-20%) spread heterogeneously across a system of laminar organization. In the
human brain, there are six layers (L1-L6) while in rodents there are only five (rodents do not
possess L4) (Heidbreder & Groenewegen, 2003). Across layers, composition and connectivity vary,
but functional characteristics of IN/P-cell connections are relatively conserved. INs wield strong,
differential control over local circuitry and are able to synchronize P-cell spiking throughout the
mPFC (Sparta et al., 2014). In rodents, cells located in L1 are thought to be exclusively GABAergic
INs (Riga et al., 2014). L1 INs receive excitatory input from the thalamus and facilitate dendritic
inhibition of L2/3 P-cells (Cruikshank et al., 2012). BC/P-cell perisomatic inhibitory networks are
seen in L2/3 and L5. P-cells in L2/3 and L5 receive excitatory inputs from the thalamus, the
contralateral mPFC, the vHPC, and the BLA. These P-cells project to various brain areas
depending their location within the mPFC. In the PL, L2/3 P-cells projects to the BLA, while in
the IL, L2/3 and L5 P-cells project to the BLA (Ferreira et al., 2015; Zaitsev, Povysheva, GonzalezBurgos, & Lewis, 2012). P-cells in L2/3 of the PL are involved in fear expression while P-cells in
L2/3 and L5 of the IL are involved in the extinction of conditioned fear (Figure 5) (Sierra-Mercado

12

et al., 2011). It is vital to make these distinctions, as they demonstrate that even within L2/3 of the
mPFC, IN/P-cell connections mediate different anxiety-related processes.

Figure 5| Basic neural connections implicated in fear. Left: The circuitry involved in fear expression.
Emotional memories from the hippocampus (HPC) interact with the prelimbic cortex (PL) which regulates
behavioral output via the amygdala (BLA and CeA). Right: The circuitry involved in fear extinction. The
HPC and basolateral amygdala (BLA) interact with the infralimbic cortex (IL) to facilitate fear extinction.
Behaviors reflective of fear extinction are produced by the IL via the extended amygdala (ITC) and central
amygdala (CeA). Neuronal plasticity associated with extinction learning is represented in pink. Adapted
from Sierra-Mercado et al., 2011.

The BLA is comprised of P-cells and multiple IN subtypes including PV+BCs and
CCK+BCs (Ehrlich et al., 2009; Freese & Amaral, 2005). P-cells receive inhibitory input from
local BCs and excitatory input from cortical areas via the external capsule (EC), a white matter
fiber tract containing clusters of P-cell axons (Little & Carter, 2013). Excitation of P-cells in the
BLA correlates with anxiety-like behavior (Johansen et al., 2010). Perisomatic inhibition,
facilitated by CCK+BCs and PV+BCs, has been observed in electrophysiology recordings from
P-cells in the BLA (Freund, 2003). PV+BCs and CCK+BCs receive excitatory signals from local
and distant P-cells (via the EC) and inhibitory signals from local INs (Faber, Callister, & Sah,
2001; Rainnie, Asprodini, & Shinnick-Gallagher, 1993). Studies have been performed on the
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underlying molecular components of perisomatic inhibitory synapses in the vHPC, however less
is known regarding similar circuits in the BLA (Barsy et al., 2017; Freund & Katona, 2007;
Trouche, Sasaki, Tu, & Reijmers, 2013). Functional studies on neurotransmitter release in BC/Pcell synapses are needed to understand how behavioral output associated with anxiety is regulated
in the BLA.

The Neurochemical Correlates of Anxiety - GABA and Glutamate
Neuronal circuits in the BLA, mPFC, and vHPC possess extensive γ-aminobutyric acid
(GABA) and glutamate neurotransmitter systems (Bystritsky, Khalsa, Cameron, & Schiffman,
2013). GABA is the principle inhibitory neurotransmitter in the brain while glutamate is the
principle excitatory neurotransmitter. Balance between GABAergic and glutamatergic activity is
critical for normal fear and anxiety-related processing (Möhler, 2002). Excess GABAergic activity
can be anxiolytic but can also impair cognition. Insufficient GABAergic activity can result in
increased anxiety (Möhler, 2002). Chronic deficits in GABAergic activity contribute to the
pathophysiology of anxiety disorders; anti-anxiety medications including benzodiazepines and
gabapentinoids enhance GABAergic activity (Sills, 2006). Alterations to glutamate transmission
have also been shown to be effective in augmenting anxiety disorders (Dawson & Watson, 2009),
as glutamate is involved in the pathways underlying normal and pathological anxiety states
(Bystritsky et al., 2013).
The effects of neuronal inhibition differ across cell types, circuits, and brain areas. When
P-cells are inhibited, they no longer release glutamate onto their projection targets. On the contrary,
inhibition of INs prevents IN-mediated inhibition; resulting in P-cell disinhibition (Andrási et al.,
2017). Accordingly, it is important to examine neuronal inhibition at the cellular and circuit level
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to more readily understand its implications in anxiety. GABA binds to the GABAA receptor, a
ligand-gated ion channel. Upon binding, the channel opens and chloride (Cl-) anions flow inward
(U. Rudolph & Antkowiak, 2004). Chloride influx induces electrical events known as inhibitory
postsynaptic currents and potentials (IPSCs and IPSPs). As a result, hyperpolarization, action
potential inhibition, and decreased neurotransmitter release occur (Amir, Michaelis, & Devor,
1999). GABAA receptors are widespread, expressed in multiple cellular domains (i.e. terminals,
somas, and axons) and cell types not exclusively involved in anxiety (Freund, 2003; Freund &
Katona, 2007). In addition to the GABAergic system, the glutamatergic system regulates anxietyrelated neuronal output from P-cells.
Proper glutamatergic transmission is required for anxiety states (Bystritsky et al., 2013).
The glutamate receptors most pertinent to anxiety-related circuits are the AMPA and NMDA
subtypes. As a whole, glutamatergic activity shows cell-type specific dynamics in modulating
anxiety-related neuronal output (Nyíri et al., 2003). For example, long-term potentiation,
implicated in storage of traumatic memories, relies on the NMDA receptors within Schaffer
collaterals of the hippocampus (Harris & Cotman, 1986). Additionally, AMPA receptors on P-cells
in the BLA are redistributed from dendritic stores into spines following severe stress (Hubert, Li,
Rainnie, & Muly, 2014).

Molecular Components of GABAergic and Glutamatergic Neurotransmission
GABA and glutamate neurotransmission are modulated by G protein-coupled receptors
(GPCRs) and voltage-gated calcium channels (CaVs). Located in the transmembrane domain,
GPCRs are signal transduction proteins which interact with molecules in the extracellular and
intracellular environment, as well as other transmembrane receptors (Trzaskowski et al., 2012).

15

There are numerus families and subtypes of GPCRs which couple to different subunits. GPCRs in
the mPFC, vHPC, and BLA are coupled to the Gi alpha subunit (Gαi), including metabotropic
GABA and glutamate receptors (Lee et al., 2015; Lenkey et al., 2015; Talani & Lovinger, 2015;
Zoppi et al., 2011). These GPCRs are involved in a variety of anxiety-related physiological
processes including behavior and mood regulation (Swanson et al., 2005). For this reason, Gαi
receptors are the target of several pharmaceutical anxiety treatments. Gαi receptors are activated by
ligand binding (whether endogenous or synthetic) and exert an inhibitory effect on cAMP and
calcium, two major internal singling molecules. As a result, calcium-mediated processes and
cAMP-dependent signal transduction pathways are inactivated (Scotter, Graham, & Glass, 2009).
Fundamentally, CaVs are protein complexes consisting of several subunits (α1, β, α2δ, and
γ) which mediate calcium ion entry into a cell (Figure 6). There are two distinct classes of CaVs
based on their voltage-gating properties; high voltage-activated (HVA) and low voltage-activated
(LVA). The phrase ‘voltage-gated’ is derived from the closed state of these channels under resting
membrane

potential

conditions.

Only a strong enough membrane
depolarization

(i.e.

an

action

potential) will release this voltagegate (Stotz, 2001). Within each
class

of

CaV,

subtypes

are

determined by the α1 subunit. The
importance of the α1 subunit cannot
be stressed enough, as it forms the
calcium-selective

ion

channel

Figure 6| Schematic of a voltage-gated calcium channel
complex. CaVs are composed of a pore-forming subunit (α1) and
several ancillary subunits. The α1 subunit functions as a voltage
sensor, binding site, and permeable ion channel. The β subunit
provides stability and modulates activation of α1. The α2δ subunit
enhances expression and regulation of α1. The γ subunit is not well
understood but does not appear to regulate channel function.
Adapted from Marrero-Rosado et al., 2014; Hannon & Atchison,
2013.
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through which calcium enters the cell (Williams et al., 1992). The α1 subunit can detect changes
in membrane potential and contains binding sites for pharmaceutical antagonists (Catterall, 2011;
Zamponi, 2016). From ten known α1 subunits there are five known CaV isoforms. The isoforms
and their respective α1 subunit encoding genes (in parenthesis) are as follows: L-type (CaV1.1,
CaV1.2, CaV1.3, CaV1.4), P/Q-type (CaV2.1), N-type (CaV2.2), R-type (CaV2.3), and T-type
(CaV3.1, CaV3.2, CaV3.3) (Catterall, 2011). The remaining CaV subunits serve α1; enhancing its
expression (δ), stabilizing its conformation (β), and regulating its activation and inactivation
kinetics (β, α2δ) (Hannon & Atchison, 2013).
Of the numerous α1 subunits, those encoded by CaV2.1, CaV2.2, and CaV2.3 (P/Q-, N-, and
R-type channels) are most involved in mediating signal transduction in GABAergic and
glutamatergic cells (Catterall, 2011; Zamponi, 2003). Additionally, CaV2 channels have been
shown to modulate neuronal firing through coupling to calcium-activated potassium channels
(Alviña & Khodakhah, 2008; Loane et al., 2007). During membrane depolarization, CaV2 opens
and allows calcium entry into the neuron, which induces numerous physiological events. For
Figure 7| Proposed mechanism of
CaV2.2-mediated
anxiogenic
signaling. Anxiety-related signaling
is propagated by excitatory pathways
in areas like the vHPC and BLA.
Action potentials travel down the
presynaptic axon and into the
terminal, whereby CaV2.2 is
activated and calcium (Ca2+) enters
the cell. Neurotransmitters (blue
circles) are released into the synapse
and activate Ca2+ entry through
postsynaptic
glutamate
(Glu)
receptors.
Increased
Ca2+
concentration further propagates
anxiogenic signaling through the
postsynaptic cell and beyond.
Adapted from Schmidtko et al., 2010;
Hannon & Atchison, 2013.

instance, calcium interacts
with SNARE proteins to
fuse

neurotransmitter

vesicles to the presynaptic
terminal, where subsequent
exocytosis leads to synaptic
transmission
2012).
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entry through CaV2.1 and CaV2.2 channels initiates the release of glutamate and GABA in fast
synapses. More specifically, it has been discovered that CaV2.2 channels regulate GABA release
from presynaptic CCK+INs in the vHPC (Szabo et al., 2014). Given the role of CCK+INs in
perisomatic inhibition of P-cells, and the role of excess P-cell activity in anxiety-related behaviors
(Figure 7), CaV2.2 channels are a critical research target for anxiety disorders (Kurihara & Tanabe,
2003; Lee et al., 2015; Lee, 2013; Szabo et al., 2014).

Modulation of the N-type Channel and Anxiety Implications
CaV2.2 modulation is a current target for treating neuropathic pain (Hannon & Atchison,
2013) and has emerged as a possible means of treating anxiety (Newton & Messing, 2009).
Previous studies have found that mice lacking CaV2.2 display reduced anxiety levels (Saegusa,
2001), and current research aims to dissect the role CaV2.2 blockers play in anxiety. In nature, a
highly-specific CaV2.2 blocker is found in the venom of the cone snail, Conus magus. Known as
‘w-Conotoxin GIVA’ when isolated, this peptide neurotoxin show affinity only for CaV2.2
(McCleskey et al., 1987). Zinconotide and Leconotide, synthetic w-Conotoxins used to treat
neuropathic pain, have strong yet poorly-understood anxiety correlates (Kolosov, Aurini, Williams,
Cooke, & Goodchild, 2011; Schmidtko, Lötsch, Freynhagen, & Geisslinger, 2010; Scott, Wright,
& Angus, 2002). The GABA analogue drugs Gabapentin and Pregabalin have seen increasing offlabel use to treat anxiety disorders. Typically used to treat seizures and nerve pain, Gabapentin and
Pregabalin target the α2δ subunit, indirectly modulating CaV2.2 (Sills, 2006). By modulating
CaV2.2, the side effects associated with GABA modulation (i.e. benzodiazepines) can be bypassed.
It is important to state that these drugs are not approved as a primary treatment for anxiety disorders.
However, the increasing and successful use of CaV2.2 modulators in treating anxiety disorders
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prompts research into their functional role in anxiety-related neuronal circuits (Lee, 2013; Lotarski
et al., 2011).
CaV2.2 channels are modulated by a variety of GPCRs. One form of modulation is voltagedependent inhibition facilitated by the binding of the G beta-gamma complex (Gβγ) to the poreforming subunit of CaV2.2 channels (Ikeda, 1996). Two inhibitory mechanisms can occur as a
result. In one mechanism, Gβγ induces a shift in the voltage-dependent activation properties of
CaV2.2 channels, which then require larger-than-normal depolarizations to open (Zamponi &
Currie, 2013). Alternatively, GPCRs can inactivate CaV2.2 through a ‘hinged lid’ mechanism,
closing the ion channel-forming subunit, a1 (Stotz, 2001). In either mechanism, calcium entry
through CaV2.2 is limited or blocked, and subsequent neurotransmitter release from presynaptic
terminals is inhibited. There are a wide variety of GPCRs that exhibit inhibitory effects on CaVs,
but a specific family has been shown to extensively couple with CaV2.2 in anxiety-related brain
areas. Cannabinoid receptors, part of the endocannabinoid system, are a specific family of
primarily Gαi GPCRs heavily implicated in anxiety (Haller, Bakos, Szirmay, Ledent, & Freund,
2002).

The Endocannabinoid System and Anxiety
The endocannabinoid (eCB) system is a network of primarily Gαi GPCRs and ligands
known to modulate synaptic transmission throughout the brain. Of the two cannabinoid receptor
types (CB1 and CB2), CB1 is the major synaptic constituent of the eCB system, heavily expressed
in CCK+INs (Lutz, Marsicano, Maldonado, & Hillard, 2015). CB1 is activated by endogenous
cannabinoid molecules like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), as well as
exogenous cannabinoids like THC (Pagotto, Marsicano, Cota, Lutz, & Pasquali, 2006).
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Cannabinoids act as retrograde feedback
inhibition messengers; postsynaptic cells
synthesize 2-AG/AEA, which bind to CB1
receptors on the presynaptic terminal,
suppressing

neurotransmitter

release

(Figure 8). CB1-mediated inhibition occurs
in two general forms; phasic and tonic.
Phasic inhibition occurs as a result of
Figure 8| eCB-mediated feedback inhibition system in
2+
postsynaptic depolarization, thus is CA3. Calcium (Ca ) entry through CaV2.2 in the
postsynaptic P-cell induces anandamide synthesis.
generated in response to specific Anandamide binds to cannabinoid receptor 1 (CB1) on the
presynaptic cholecystokinin interneuron (CCK+IN)
terminal. Ca2+ entry though CaV2.2 is then inhibited,
postsynaptic signals. Tonic inhibition is the preventing GABA release. Adapted from Sharkey &
Pittman, 2005.

result of basal CB1 activity, and occurs

irrespective of postsynaptic signals (Lee et al., 2015; Soltesz et al., 2015). Mechanistically, CB1
modulates neurotransmitter release by coupling to and downregulating CaVs (Wilson, Kunos, &
Nicoll, 2001). By inhibiting calcium entry through CaVs, processes like vesicular fusion are
prevented (Catterall, 2011). In the CA3 region of the vHPC, CB1 was shown to specifically couple
to CaV2.2, but it is not known if this coupling is conserved in the BLA.
The eCB system has been shown to differentially modulate synaptic transmission across
different brain regions, cell types, and synapses. Heavy integration of the eCB system has been
observed in the HPC, PFC, and amygdala, where it is thought to have modulatory effects on fear
and anxiety processing (Lutz et al., 2015). At GABAergic synapses, eCB-mediated inhibition is
known as depolarization-induced suppression of inhibition (DSI), and in glutamatergic synapses,
it is known as depolarization-induced suppression of excitation (DSE) (Ramikie & Patel, 2012).
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DSI and DSE are short-term effects, as eCB-mediated synaptic modulation follows a negativefeedback loop. Neurons containing CB1 are classified into two groups; high CB1-expressing cells,
which are sparsely distributed in the BLA and cortical areas, and low CB1-expressing cells, which
are more evenly dispersed (Marsicano & Lutz, 1999; Yoshida et al., 2011). Research on cellspecific CB1 expression has revealed high selectivity for CCK+INs over other INs. In the BLA,
95% of high CB1-expressing cells and 90% of low CB1-expressing cells were CCK+INs
(Marsicano & Lutz, 1999). Contrarily, CB1 expression is largely absent from PV+INs. In addition
to CCK+IN selectivity, CB1 has been shown to couple with CaV2.2. In rat sympathetic neurons,
N-type calcium currents were inhibited by CB1 agonists, inhibition which was then reversed by
CB1 antagonists (Guo & Ikeda, 2004). Furthermore, CB1-CaV2.2 coupling appears to be prevalent
in CCK+INs. In the CA3 region of the vHPC, CaV2.2-dependent GABA release from CCK+IN
terminals was shown to be inhibited with CB1 agonists (Szabo et al., 2014).
It is widely accepted that there is a strong correlation between the eCB system and anxiety,
but this correlation is not fully understood (Lutz et al., 2015). eCB system modulation shows
potential for treating anxiety disorders, a well-known example of which being the anxiolytic
properties of THC (Onaivi, Green, & Martin, 1990). In both humans and rodents, it has been shown
that cannabinoids can influence anxiety-like symptoms in a biphasic manner; low doses produce
anxiolytic effects while high doses produce anxiogenic effects (Moreira, Grieb, & Lutz, 2009; Rey,
Purrio, Viveros, & Lutz, 2012). Research suggests that CB1 modulation has opposite effects on
anxiety-like behavioral output in glutamatergic and GABAergic cells. Knockout mice lacking CB1
in all glutamatergic cells show increased anxiety-like behaviors, while knockout mice lacking CB1
in all GABAergic cells show reduced anxiety-like behaviors (Häring, Kaiser, Monory, & Lutz,
2011). CB1-mediated anxiety effects are not confined to GABAergic and glutamatergic activity
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however, and are different when isolating specific brain regions (Rovira-Esteban et al., 2017;
Szabo et al., 2014). Accordingly, more detailed neurophysiological research must be conducted on
the role of CB1 in cell populations and brain regions implicated in anxiety.

Implications of CCK and CCK+INs in Anxiety
CCK and CCK+INs have well-established links to anxiety which originate from their role
in neuronal circuits. CCK, the CCK receptor (CCKB), and CCK+INs are highly expressed in the
limbic system (Vanderhaeghen, Signeau, & Gepts, 1975). As a neuropeptide, CCK is found in
vesicles and displays synaptic properties similar to classical neurotransmitters (Emson, Lee, &
Rehfeld, 1980). CCK is associated with anxiety through its interactions with CCKB. In healthy
patients, CCK administration induces panic attacks (Montigny, 1989) while CCKB antagonists
block these panicogenic effects (Bradwejn, Koszycki, Couetoux du Tertre, van Megen, & et al.,
1994). In rodents, CCK agonists produce anxiety-like behaviors (Frankland, Josselyn, Bradwejn,
Vaccarino, & Yeomans, 1996) while CCKB antagonists attenuate them (Josselyn et al., 1995).
Binding of CCK to CCKB has been shown to modulate the neuronal properties of classical
neurotransmitters (Altar & Boyar, 1989). Interactions exist between CCK and GABA, dopamine,
and endocannabinoid neurotransmission (Altar & Boyar, 1989; Chhatwal et al., 2009; Lanza &
Makovec, 2000).While these interactions remain relatively understudied, they represent potential
underlying mechanisms by which CCK is linked to anxiety.
CCK+INs display a distinct regulatory role over anxiety-like behaviors. Along with
PV+INs, CCK+INs establish GABAergic connections onto the soma of P-cells in several brain
regions including the BLA, HPC, and PFC (Freund & Katona, 2007; Sparta et al., 2014). In the
BLA, CCK+INs innervate up to eight hundred P-cells each (Vereczki et al., 2016), and are thought
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to prevent anxiety-like responses from occurring in non-threatening situations (Freund, 2003;
Mascagni & McDonald, 2003; Truitt et al., 2009). When CCK+INs in the BLA are lesioned, rats
display increased anxiety-like behaviors (Truitt et al., 2009), a phenotype thought to be the result
of lost GABAergic and CCKergic activity. Additionally, it has been proposed that by acting with
the eCB system, CCK+INs modulate fear inhibition and extinction (Bowers, Choi, & Ressler,
2012). CCK+INs likely modulate fear extinction at the level of the BLA by inhibiting ‘extinction’
neurons (Duvarci & Pare, 2014). CCK+IN synapses are remodeled by fear extinction, displaying
increased CB1 expression and thus decreased inhibition of extinction neurons (Duvarci & Pare,
2014; Trouche et al., 2013). Given their expression of CaV2.2 and CB1, role in perisomatic
inhibition, as well as integration in limbic system structures, CCK+INs are essential targets for
anxiety research.

Master’s Thesis Research
Research Motivations
We are motivated to determine the role of CaV2.2 in GABA release from CCK+INs onto
P-cells in the BLA. It has been demonstrated in the CA3 region of the HPC that GABA release in
CCK+IN/P-cell synapses is eliminated by blocking CaV2.2 (Szabo et al., 2014). If conserved,
CaV2.2 may be a potential target for mediating anxiety at the level of the amygdala. Additionally,
we are motivated to determine the role of CB1 in CCK+IN/P-cell synapses in the BLA. Given
findings which indicate CB1 inhibits CaV2.2 and subsequently GABA release from CCK+INs onto
P-cells in the HPC (Szabo et al., 2014), we are interested in examining this system in the BLA.
CB1 shows promise in the development of novel anxiety treatments, but a greater understanding
of its role in anxiety-related circuits is needed. Research describing the role of the IL in fear
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extinction and its connections to the BLA motivates us to determine if CaV2.2 regulates presynaptic
transmitter release and intrinsic firing properties in this region of the mPFC. P-cells in the mPFC
receive dendritic inhibition from INs in superficial layers and perisomatic inhibition from proximal
BCs (Riga et al., 2014). However, little is known about the role of CaV2.2 in regulating GABA
release in these inhibitory synapses.

Research Questions
Chapter 1: Is GABA release in CCK+IN/P-cell synapses in the BLA CaV2.2-dependent?
P-cells carry the bulk of information from the BLA to other brain areas implicated in anxiety.
Previous research shows that excitation of P-cells in the BLA increases anxiety-like behaviors
(Johansen et al., 2010). Local INs expressing the peptide cholecystokinin (CCK+INs) synapse onto
the soma of P-cells, forming a system of perisomatic inhibition (Freund, 2003). Previous studies
in the CA3 region of the HPC have shown that the GABA release from CCK+INs onto P-cells is
dependent on CaV2.2 (Szabo et al., 2014). If this circuitry is conserved in the amygdala, Cav2.2
could be a potential pharmacological target for regulating anxiety at the level of the BLA.
Chapter 2: What is the role of CB1 in CCK+IN/P-cell synapses in the BLA? Does CB1
exhibit tonic and/or phasic inhibition of GABA release? The eCB system and anxiety-like behavior
are strongly correlated (Lutz et al., 2015). Similarly, P-cell excitability in the BLA is correlated
with anxiety-like behavior (Davis, Rainnie, & Cassell, 1994). CB1 has been shown to inhibit
neurotransmitter release in both glutamatergic and GABAergic synapses (Azad, 2003) in both
ligand dependent (tonic) and independent (phasic) manners (Farrant & Nusser, 2005; Neu et al.,
2007; Roberto et al., 2010). When GABA release is suppressed, P-cells are disinhibited and more
excitable. In the hippocampus, CB1 is present in and regulates transmitter release in CCK+IN/P-
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cell synapses (Yoshida et al., 2011). We are interested if this circuitry is conserved in the amygdala,
and by what means (phasic and/or tonic) CB1 mediates GABA release from CCK+INs onto P-cells
in the BLA.
Chapter 3: Is transmitter release in IN/P-cell synapses in the IL CaV2.2-dependent? Is
GABA release in CCK+IN/P-cell synapses in the IL CaV2.2-dependent? Are intrinsic firing
properties of P-cells in the IL regulated by CaV2.2? Calcium channel physiology is relatively
understudied in the infralimbic area of the mPFC. Our initial goal is to determine if, and to what
degree, CaV2.2 is present in presynaptic IN inputs onto P-cells in the IL. Upon determining the
role of CaV2.2 in IN terminals, we will specifically target CaV2.2 in CCK+INs. Comparisons can
be drawn about the properties of this IL circuit to those in the BLA and HPC. We are also interested
in determining if CaV2.2 modulates the intrinsic firing properties of P-cells in the IL. CaV2.2 makes
a significant contribution to intrinsic firing properties of P-cells in the cerebellum (Alviña &
Khodakhah, 2008), and couples to calcium-activated potassium channels in the HPC to modulate
the after-hyperpolarization phase of action potentials (Loane et al., 2007).

Summary of Findings
Chapter 1: I present fluorescence images depicting CCK+IN expression in the BLA as
well as electrophysiological data on the role of CaV2.2 in CCK+IN/P-cell synapses. Cells were
exposed to a CaV2.2 antagonist (ω-Conotoxin GIVA), following which IPSC peak amplitude
decreased by an average of 51%. Results demonstrate that the release of GABA in CCK+IN/P-cell
synapses in the BLA is partially CaV2.2-dependent.
Chapter 2: I present immunofluorescence images depicting CCK+IN and CB1 expression
in the BLA and HPC, quantifying the level colocalization in each area. Second, I present
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electrophysiology data on the sensitivity of GABA release in CCK+IN/P-cell synapses to phasic
and tonic inhibition. A total of two cells were exposed to a CB1 agonist (2-AG) and antagonist
(AM251). IPSC peak amplitude decreased by 26% following exposure to 2-AG and increased 34%
following exposure to AM251. Results can be used to confirm the findings of Rovira-Esteban and
colleagues (2017), who describe tonic and phasic CB1-mediated inhibition of transmitter release
in CCK+IN/P-cell synapses in the BLA.
Chapter 3: I present electrophysiological data on the role of CaV2.2 in regulating GABA
release from general INs, GABA release from specifically CCK+INs, and in P-cell intrinsic firing
properties in the IL. Following exposure to ω-Conotoxin GIVA, IPSC peak amplitude in IN/P-cell
synapses decreased an average of 46% across six cellular recordings. In CCK+IN/P-cell synapses,
IPSC peak amplitude decreased an average of 9% over eight cellular recordings in response to ωConotoxin GIVA. Additionally, ω-Conotoxin GIVA did not significantly affect the firing pattern
and spike frequency of P-cells. These results can be used to demonstrate that 1) GABA release
from INs in the IL is partially CaV2.2-dependent, 2) GABA release from CCK+INs in the IL is not
significantly CaV2.2-dependent, and 3) P-cell firing properties are not significantly modulated by
CaV2.2 in the IL.
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CHAPTER 1: CAV2.2-MEDIATED GABA RELEASE FROM CCK+ INTERNEURONS
ONTO PYRAMIDAL CELLS IN THE BASOLATERAL AMYGDALA
Abstract
The basolateral nucleus of the amygdala (BLA) is an interconnected limbic system structure
implicated in anxiety. Normal function of the BLA relies on a balance between excitatory and
inhibitory signaling, which is known to be disrupted in anxiety disorders like post-traumatic stress.
Excitatory activity in the BLA is facilitated by glutamatergic pyramidal cells (P-cells), which when
directly stimulated produce anxiety-like behavior. P-cells are regulated by inhibitory signaling
from local interneurons (INs) including those that contain the neuropeptide cholecystokinin
(CCK+). It has been demonstrated that CCK+INs regulate anxiety-like behavior at the level of the
BLA, likely due to their inhibitory control over local neuronal circuits. The release of inhibitory
neurotransmitter (GABA) from CCK+INs is regulated by voltage-gated calcium channels (CaVs),
of which there are multiple subtypes. In the hippocampus, GABA release from CCK+INs is
entirely dependent on the N-type calcium channel (CaV2.2). It is not known if this role of CaV2.2
is conserved in the BLA, representing a potential target by which inhibition of anxiety-related
output from the BLA is regulated. In this study, we determined the role of CaV2.2 in GABA release
in CCK+IN/P-cell synapses in the BLA. To visualize the neuroanatomy of CCK+INs, a triple
transgenic mouse model (CCK-Dlx5/6-tdT) was generated which labelled CCK+INs with red
fluoresce (via the tdTomato fluorophore). To evoke GABA release from CCK+INs, a second triple
transgenic mouse model (CCK-Dlx5/6-ReaChR) was generated in which CCK+INs express redactivatable channelrhodopsins. Following optogenetic stimulation, inhibitory postsynaptic
currents (IPSCs) were recorded in P-cells. The sensitivity of GABA release to CaV2.2 block was
determined through bath addition of w-Conotoxin GIVA (CTX). Following CaV2.2 block, average
IPSC peak amplitude decreased by 51% (n = 7 cells, SD = 14%, SEM = 5%) compared to control
conditions, which was determined to be statistically significant (p = 0.0046, one-tailed paired tTest). Our results indicate that GABA release from CCK+INs in the BLA is partially CaV2.2dependent, contrasting total CaV2.2-dependency reported in the hippocampus. We propose that
CCK+IN/P-cell synapses are differentially regulated by CaV2.2 in the BLA and hippocampus. As
a result, CaV2.2 modulation likely has region-specific implications in anxiety.
Introduction
Fear is the result of an immediate, recognizable threat while anxiety is the result of
perceived, imprecise threats (Steimer, 2002). Both fear and anxiety produce emotional,
physiological, and behavioral changes intended for survival and are products of similar
neurological activity. Anxiety can become dysfunctional however, occurring in inappropriate
situations and causing disruptions to normal stimulus processing. This can manifest as anxiety
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disorders in humans and anxiety-like behaviors in animal models. Common in both stations is
abnormal activity in brain regions like the amygdala (Ritu et al., 2013). The amygdala is a critical
brain region for fear-related learning and memory as well as anxiety-related behavioral output
(Phelps et al., 2004; Roozendaal, McEwen, & Chattarji, 2009). Proper function of the amygdala
requires balance between excitatory and inhibitory signaling. This balance is known to be
disrupted by chronic anxiety and is observable in anxiety disorders like post-traumatic stress
(PTSD) (Milad et al., 2009). The molecular components which regulate the balance between
excitatory and inhibitory activity in the amygdala are not fully understood but serve as vital targets
for anxiety research.
The amygdala is composed of multiple nuclei with diverse functions and connections. The
central amygdala (CeA), composed of the lateral nucleus (CeL) and medial nucleus (CeM), is
considered an inhibitory mediator of the basolateral amygdala (BLA) (Capogna, 2014; Janak &
Tye, 2015). The BLA, composed of the lateral nucleus (LA) and basal nucleus (BA), is considered
the main source of excitatory neuronal output from the amygdala to brain regions involved in
anxiety like the hippocampus (HPC) and prefrontal cortex (PFC) (Gale, 2004). The CeA is
predominantly composed of GABAergic cells, containing both local and projection interneurons
(INs). The cytoarchitecture of the BLA is similar to that of the PFC, as a majority (approximately
80%) of neurons are glutamatergic pyramidal cells (P-cells) while a minority (approximately 20%)
are GABAergic INs (Spampanato, Polepalli, & Sah, 2011). It is within the connections established
between these two cell types that neuronal output is modulated.
P-cells are known for their distinct piriform morphology, lengthy apical dendrites, and farreaching axonal projections. Within the BLA and PFC, P-cells display similar intrinsic properties
including regular spiking, non-adapting firing patterns and moderate spike frequency (Rainnie et
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al., 1993). P-cells are targeted by several IN types (Freund, 2003); those which synapse onto the
body of P-cells (soma) are termed basket cells (BCs) (Armstrong & Soltesz, 2012). BCs have a
round morphology and branching dendrites that are involved in perisomatic inhibition in brain
regions like the BLA, PFC, and HPC (Ferreira et al., 2015; Neu et al., 2007; Veres et al., 2017).
Perisomatic inhibition is a form of feedback inhibition wherein P-cell activation stimulates the
release of GABA from presynaptic BC terminals onto the P-cell body, suppressing excitatory
activity (Freund & Katona, 2007). Subtypes of BCs, distinguishable by their firing patterns and
neurochemical markers, differentially regulate P-cells through unique synaptic properties (Duvarci
& Pare, 2014). Of particular interest to anxiety research are cholecystokinin-containing (CCK+)
BCs.
CCK is a neuropeptide with profound anxiogenic and panicogenic properties (Montigny,
1989; Frankland et al., 1996; Rotzinger & Vaccarino, 2003). CCK+INs have been shown to
regulate anxiety-like behavior at the level of the BLA, likely due to their role in neuronal circuits
(Truitt et al., 2009). In the HPC and PFC, it has been demonstrated that CCK+BCs regulate the
activity of P-cells through perisomatic inhibition (Freund & Katona, 2007; Whissell et al., 2015),
however less functional data is available on their connectivity within the BLA (Duvarci & Pare,
2014). It has been suggested that CCK+BCs in the BLA are analogous with cortical CCK+BCs, as
both have relatively slow, adapting spiking patterns and are likely to respond to slow, asynchronous
inputs (Bartos & Elgueta, 2012; Jasnow et al., 2009). However, there are multiple subtypes of
CCK+INs across brain regions with different intrinsic properties (Jasnow et al., 2009). These
differences are thought to be the result of specific ion channel variations (Jasnow et al., 2009).
In multiple brain regions, CCK+INs have been found to express N-type calcium channels
(CaV2.2) (Freund & Katona, 2007; Katona et al., 2001; McDonald & Mascagni, 2001; Szabo et al.,
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2014). CaV2.2 is a voltage-gated calcium channel (CaV) subtype critically involved in
neurotransmitter release (Szabo et al., 2014). Located in the transmembrane domain, the ion
channel-forming subunit of CaV2.2 (a1B) opens in response to membrane depolarization (Loane et
al., 2007; Williams et al., 1992). Subsequently, calcium ions enter the neuron and interact with the
SNARE protein complex to facilitate synaptic vesicle fusion and neurotransmitter exocytosis
(Südhof, 2012). Functional studies have revealed that in the HPC, GABA release from CCK+IN
is entirely dependent upon CaV2.2. However, the role of CaV2.2 role in regulating neurotransmitter
release from CCK+INs has not been functionally described in the BLA.
Currently, CaV2.2 is a target for treating neuropathic pain (Scott et al., 2002), but shows
promise as a novel target for anxiety disorders (Newton & Messing, 2009). It has been proposed
that the anxiolytic effects of Gabapentin (Lotarski et al., 2011) may be due to α2δ-dependent effects
on CaV2.2 channels (Cassidy, Ferron, Kadurin, Pratt, & Dolphin, 2014; Zamponi, 2016), wherein
neurotransmitter release is suppressed and excitatory synapses are downregulated throughout the
brain (Eroglu et al., 2009). CaV2.2 antagonists have been found to be anxiogenic; administration
of Zinconotide (Prialt) can produce anxiety and panic attacks (McCleskey et al., 1987; Scott et al.,
2002). While it has been shown CaV2.2 is implicated in anxiety-related neurotransmission, the
underlying molecular mechanics are poorly understood and deserve further investigation. Here, I
propose a comprehensive study combining transgenic mouse models, fluorescence microscopy,
brain slice electrophysiology, and pharmacology to test the hypothesis that GABA release in
CCK+IN/P-cell synapses in the BLA is CaV2.2-dependent.

Methods
Animal Models
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All procedures were approved by the Institutional Animal Care and Use Committee at the
University of New Hampshire (APPENDIX). To visualize the neuroanatomy of CCK+INs in the
amygdala, we performed intersectional labeling using two molecular markers: CCK and Dlx5/6.
CCK is expressed in both GABAergic and glutamatergic neurons, whereas Dlx5/6 is only
expressed in GABAergic INs. We obtained a triple transgenic mouse line via the breeding
schematic in Figure 9A. Initially, Cck-IRES-Cre mice (012706; The Jackson Laboratory) were
crossed with Dlx5/6-Flpe mice (010815; The Jackson Laboratory). Cre and Flpe are recombinases
expressed under the control of the CCK promoter and the Dlx5/6 promoter, respectively. Progeny
from this initial cross, Cck-IRES-Cre; Dlx5/6-Flpe (abbreviated CCK-Dlx5/6), were dual
transgenic mice with both alleles. Because the Dlx5/6 mutation could not be bread to homozygosity,
we selected for CCK-Dlx5/6 mice that were homozygous for CCK-Cre and heterozygous for
Dlx5/6-Flpe. To optimize the recombination efficiency, male CCK-Dlx5/6 mice were bred to
female reporter mice (Ai65(RCFL-tdT)-D; 021875; The Jackson Laboratory) which contained the
fluorescent protein tdTomato behind two recombinase target-flanked STOP cassettes. The first
STOP cassette was flanked by loxP sites (recognized by Cre) and the second was flanked by FRT
sites (recognized by Flpe). Progeny from this cross were triple-transgenic mice with the genotype
Cck-IRES-Cre; Dlx5/6-Flpe; Ai65(RCFL-tdT)-D (abbreviated CCK-Dlx5/6-tdT). In these mice,
Cre-Lox and Flpe-FRT recombination removed the two STOP cassettes, resulting in tdTomato
fluorescence in tissues that expressed both CCK and Dlx5/6, i.e. GABAergic CCK+INs
(abbreviated CCK+INs). Bright-red fluorescence is observable in the cell bodies and neuronal
processes of CCK+INs throughout the BLA (Figure 10B).
CCK is contained in glutamatergic cells in addition to GABAergic INs (Ma, DankulichNagrudny, & Lowe, 2013). This was evidenced when we bred dual-transgenic mice in which all
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CCK+ cells/tissue were labeled. Cck-IRES-Cre mice were crossed with a Cre reporter mouse line
(007914; The Jackson Laboratory) which contain the fluorescent protein tdTomato behind a single
loxP-flanked STOP cassette (Ai14(RCL-tdT)-D). The resultant progeny, Cck-IRES-Cre;
Ai14(RCL-tdT)-D (abbreviated CCK-tdT), show widespread, non-specific fluorescence in both
glutamatergic and GABAergic CCK+ cells/tissue in the BLA (Figure 10A).
To perform electrophysiological studies of CCK+IN/P-cell synapses, we used optogenetics.
Optogenetics allow for the precise study of specific cell populations related to anxiety-like
behavior (Tye & Deisseroth, 2012). The specific optogenetic tool we used was derived from
channelrhodopsin (ChR), a cation-permeable channel that opens in response to a specific
wavelength of light to cause membrane depolarization, action potentials, and neurotransmitter
release (Britt, McDevitt, & Bonci, 2012; Lin, Knutsen, Muller, Kleinfeld, & Tsien, 2013). By
embedding light-activatable cation channels in GABAergic CCK+ cells/tissue, we are able to
selectively activate presynaptic GABA release from CCK+IN terminals. To accomplish this, we
bred a second triple transgenic mouse line.
CCK-Dlx5/6 mice were bred to a mouse strain that contains an allele that codes for redactivatable channelrhodopsin (ReaChR) (Figure 9B). This mouse strain (R26 LSL FSF ReaChRmCitrine; 024846; The Jackson Laboratory) contained ReaChR and two STOP cassettes (loxPand FRT-flanked). mCitrine, a yellow-fluorescent protein, was bound to the C-terminus of ReaChR,
allowing for mapping of ReaChR expression. Progeny from this cross are triple-transgenic mice
with the genotype Cck-IRES-Cre; Dlx5/6-Flpe; R26 LSL FSF ReaChR-mCitrine (abbreviated
CCK-Dlx5/6-ReaChR). In these mice, Cre-loxP and Flpe-FRT recombination removed the two
STOP cassettes, resulting in the expression of ReaChR in CCK+INs. This strategy allowed for
stimulation of only GABAergic CCK+INs. To visualize channelrhodopsin expression both
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glutamatergic and GABAergic CCK+ cells, Cck-IRES-Cre mice were crossed with mice that
expressed

a

loxP-flanked

STOP

cassette

and

fluorescence-tagged

(EYFP,

yellow)

Channelrhodopsin 2 (ChR2) cation channels (Ai32(RCL-ChR2(H134R)/EYFP); 024109; The
Jackson

Laboratory).

Progeny

from

this

cross

were

Cck-IRES-Cre;

Ai32(RCL-

ChR2(H134R)/EYFP) mice (abbreviated CCK-ChR2) which displayed widespread EYFP
fluorescence in the transmembrane domain of CCK+ cells/tissue.
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Figure 9| Breeding schematics for triple-transgenic mouse models. Genotypes are depicted under each
mouse; oval, promotor/marker; rectangle, recombinase; triangle, recombinase target; hexagon, STOP
cassette. A| CCK-Dlx5/6-tdTomato breeding scheme. Top: Initial mating between Cck-IRES-Cre (black)
and Dlx5/6-Flpe (white) mouse lines gave rise to CCK-Dlx5/6 progeny (brown). Middle: Second mating
of CCK-Dlx5/6 mouse to Ai65(RCFL-tdT)-D mouse (grey) gave rise to CCK-Dlx5/6-tdT progeny (red).
Combined action of Cre-loxP and Flpe-FRT recombination removed both STOP cassettes. Bottom:
tdTomato is expressed in GABAergic CCK+ cells, represented in an intersectional breeding diagram. B|
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CCK-Dlx5/6-ReaChR breeding scheme. Top: Initial cross between Cck-IRES-Cre (black) and Dlx5/6-Flpe
(white) mice produced CCK-Dlx5/6 offspring (brown). Middle: Second cross between CCK-Dlx5/6 and
R26 LSL FSF ReaChR-mCitrine mice (ash) produced CCK-Dlx5/6-ReaChR progeny (yellow). Cre-loxP
and Flpe-FRT recombination removed both STOP cassettes. Bottom: Red-activatable channelrhodopsin
(ReaChR) was expressed in CCK+ GABAergic cells, represented in an intersectional breeding diagram.

Genotyping
To confirm the presence of alleles in a given mouse, we performed genotyping using tail
biopsy. Tail biopsy was performed in P7-P9 pups. Genomic DNA was extracted using the Phire
Animal Tissue Direct PCT kit (F140WH; ThermoFisher) according to manufacturer instructions.
PCR was then performed with AmpliTaq Gold 360 (4398813; ThermoFisher) under the following
conditions: a hot-start of 95oC for 10 min, followed by 35 cycles of 95oC for 30 sec, 60oC for 30
sec, 72oC for 1 min, and a final step of 72oC for 7 min. Primer sequences and band size are located
in Table 1.

Mouse Line
Cck-IRES-Cre

Primers
Expected Products
F-MT: 5’-TGGTTTGTCCAAACTCATCAA
Hom: 215 bp
F-WT: 5’-GGGAGGCAGATAGGATCACA
Het: 215 and 468 bp
R-CM: 5’-GAGGGGTCGTATGTGTGGTT
WT: 468 bp
Dlx5/6-Flpe
F-TG: 5’TG: 406 bp
CAGAATTGATCCTGGGGAGCTACG
IC: 200 bp
R-TG: 5’*PCR does not differentiate
CCAGGACCTTAGGTGGTGTTTTAC
Hom and Het mice
F-IC: 5’-CAAATGTTGCTTGTCTGGTG
R-IC: 5’-GTCAGTCGAGTGCACAGTTT
Ai65(RCFL-tdT)-D
F-MT: 5’-CTGTTCCTGTACGGCATGG
Hom: 196
and
R-MT: 5’-GGCATTAAAGCAGCGTATCC
Het: 196 and 297
Ai14(RCL-tdT)-D
F-WT: 5’-AAGGGAGCTGCAGTGGAGTA
WT: 297
R-WT: 5’-CCGAAAATCTGTGGGAAGTC
R26 LSL FSF
R-MT: 5’-CGGGCCATTTACCGTAAGTTAT Hom: 284 bp
ReaChR-mCitrine
F-IC: 5’-AAGGGAGCTGCAGTGGAGTA
Het: 284 bp and 297 bp
R-WT: 5’-CCCAAAATCTGTGGGAAGTC
WT: 297 bp
Ai32(RCLF-WT: 5’-AAGGGAGCTGCAGTGGAGTA
Hom: 253 bp
ChR2(H134R)/EYFP) R-WT: 5’-CCGAAAATCTGTGGGAAGTC
Het: 253 bp and 297 bp
F-MT: 5’-ACATGGTCCTGCTGGAGTTC
WT: 297 bp
R-MT: 5’-GGCATTAAAGCAGCGTATCC
Table 1| Primer sequences and band sizes for mouse genotyping. Information on the primer sequences
and expected PCR products for each mouse line used. F, forward primer sequence; R, reverse primer
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sequence; MT, mutant; WT, wild-type; CM, common; Hom, homozygous; Het, heterozygous; TG,
transgene; IC, internal control.

Fluorescence Stainings
Adult CCK-tdT and CCK-Dlx5/6-tdT mice (30 £ P < 120) were deeply anesthetized with
isoflurane (07-893-1389; Patterson Veterinary). Proper levels of anesthesia were confirmed
through the absence of a rear-foot reflex. Intraperitoneal injections (0.05 mL for females and 0.07
mL for males) of Euthasol euthanasia solution (710101; Virbac Co.) were delivered to the lowerright abdomen with a 26-gauge needle. Cardiac perfusions were performed using formalin solution
(HT501128; Sigma-Aldrich) to attain brain fixation. Brains were rapidly dissected and stored at
4°C in formalin solution for 24-72 hours for further fixation. 100 µm coronal brain slices were
prepared using a vibratome (VT1000 S; Leica) and transferred to a 12-well plate (Greiner BioOne). Slices were washed for ten minutes three times in PBT (0.2% Triton X (T8787; SigmaAldrich) in PBS (P3813; Sigma-Aldrich)) on an orbital rocker (SK-O180-S; Scilogex). To stain
nucleic acids and identify cell bodies, slices were incubated for one hour at room temperature in a
1:10000 dilution of SYTO-13 in PBT. SYTO-13 is a green fluorescent nucleic acid stain (S7575;
ThermoFisher). Following incubation, slices were washed twice in PBT and once in PBS before
mounting onto micro slides (48311-703; VWR) with Vectashield medium (H-1400; Vector
Laboratories) and micro cover glass (48393-221; VWR). Slides were stored at 4°C for a minimum
of 24 hours before confocal imaging.
Fluorescence stainings for CCK-Dlx5/6-ReaChR mice followed the protocol described
above, with a modification to the incubation step. CCK-Dlx5/6-ReaChR mice express the
fluorophore mCitrine rather than tdTomato. mCitrine and SYTO-13 have partially overlapping
emission spectra, so TO-PRO-3, another nucleic acid stain (T3605; Thermo-Fischer), was used
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instead (1:4000 dilution). Fluorescence studies in CCK-ChR2 mice examined the native EYFP
fluorophore, so sections were not incubated in a nucleic acid stain. Brains were sliced, washed,
and mounted in the same manner as described above.

Confocal Microscopy
Following fluorescence stainings, brain slices were imaged on one of two confocal systems.
CCK-Dlx5/6-ReaChR sections were imaged on a Leica SP8 confocal using HyVolution superresolution imaging (Huygens Software). CCK-tdT, CCK-Dlx5/6-tdT, and CCK-ChR2 slices were
imaged on a Zeiss LSM 510 Meta using accompanying LSM imaging software. A combination of
argon and helium-neon lasers were used to excite fluorophores at 488 nm, 514 nm, 543 nm, and
633 nm. For brain slices with multiple fluorescent proteins, multi-track acquisition was
implemented to avoid excitation cross-talk. A series of band- and long-pass filters were applied to
isolate emission peaks from individual fluorophores and prevent emission cross-talk. Fluorophores
and their spectra were as follows (excitation/emission (nm)): SYTO-13 (488/509), EYFP
(513/529), mCitrine (514/529), tdTomato (554/581), and TO-PRO-3 (642/661). Images were set
to either a 1024 x 1024 or 2048 x 2048 frame size. A left-to-right scan with line averaging was
used, each line being scanned eight times. The camera pinhole was kept at 1 airy unit across all
imaging. The Zeiss range indication tool was used to adjust the amplifier offset and detector gain,
preventing over/under saturation of signals. A combination of tile-scans, z-scans, and single-plane
images of the BLA were taken at 5x, 10x, 20x, 40x, and 63x. Our primary objectives were to
confirm the specificity to which our triple transgenic mouse models labelled CCK+INs and
identify the neuroanatomy of CCK+INs in the BLA.
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In Vitro Brain Slice Preparation
No less than three adult male and three adult female CCK-Dlx5/6-ReaChR mice were
deeply anaesthetized with isoflurane and decapitated. Brains were rapidly removed from the skull
and placed into chilled and oxygenated artificial cerebral spinal fluid (‘cutting’ aCSF) containing
(in mM): NaCl (130), KCl (3.5), KH2PO4 (1.1), MgCl2 (6), CaCl2 (1), dextrose (10), kynurenic
acid (2), NaHCO3 (30), ascorbate (.4), thiourea (.8), and sodium pyruvate (2) at pH 7.35 and 310
mOsm. 300 µm coronal slices containing the amygdala were prepared after mounting the brain in
a vibratome. A scalpel was used to cut the corpus callosum and obtain hemi-coronal sections.
Slices were transferred from the vibratome to a brain slice chamber (BSKH; Digitimer) containing
oxygenated cutting aCSF and kept at 37°C for 15 minutes before transferring to a second slice
chamber containing oxygenated room temperature ‘regular’ aCSF. Regular aCSF was composed
of (in mM) NaCl (130), KCl (3.5), KH2PO4 (1.1), MgCl2 (1.3), CaCl2 (2.5), dextrose (10), NaHCO3
(30), ascorbate (.4), thiourea (.8), and sodium pyruvate (2) at pH 7.35 and 300 mOsm. Slices were
allowed to stabilize for one hour before transferring to the recording chamber where they remained
for no more than two hours during patch-clamp recordings.

Electrophysiology
Our electrophysiology rig was housed on a nitrogen-fed workstation (Vision IsoStation;
Newport). On the workstation was an upright microscope (BX51WI; Olympus) equipped with
halogen (TH4-100; Olympus) and LED (Lumen 300; Prior Scientific) light sources. A CMOS
microscopy camera (01-ROL-BOLT-M-12; QImaging) and 38mm c-mount (DC50NN; Qioptiq)
were used in conjunction with capture software (Q-Capture Pro; QImaging) to perform differential
interference contrast (DIC) microscopy. DIC microscopy was used to identify brain regions under
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a 4x objective and P-cells under a 40x objective. The microscope was also equipped with an
electrophysiology system consisting of a fixed-stage platform with manual x-y translator and a
micromanipulator with a precision controller (1078-325-Y51; Sutter Instruments). Attached to the
micromanipulator was a grounding electrode (E242; Warner Instruments) and headstage (CV-7B;
Axon Instruments) connected to an amplifier (700B; Molecular Devices) and digitizer (1550A;
Molecular Devices). Data from the digitizer was processed and recorded with the Axon pCLAMP
10 software suite (Molecular Devices).
Brain slices were held under the microscope in a rectangular slice chamber (RC-27LD;
Warner Instruments) and anchored with a harp (64-0257; Warner Instruments). The slice chamber
was housed in a magnetic platform (PM-7D; Warner Instruments) mounted to the microscope
staging. Slices were kept healthy through a bath perfusion of ‘regular’ aCSF. aCSF was contained
in a 60 mL syringe (BD Instruments) mounted above the microscope and oxygenated with 95 %
O2/CO2. The perfusion was driven by a peristaltic pump (13-876; Fisher Scientific) which cycled
regular aCSF from the 60 mL syringe to the slice chamber and back through laboratory-grade
tubing (07407-71; Cole Palmer) and tubing connectors (64-1565; Warner Instruments). An IV flow
regulator (ISGRF1001; Invacare Supply) was used to control the rate of the perfusion and a valve
controller (VC-6; Warner Instruments) was used to start and stop aCSF flow.
For patch-clamp electrophysiology experiments, borosilicate glass micropipettes with tip
resistances between 4-7 mOhms were prepared using a micropipette puller (P-1000; Sutter
Instruments) and filled with intracellular solution. Recordings involving action potentials and/or
cellular firing properties utilized a potassium-based internal solution consisting of (in mM): Kgluconate (140), HEPES (10), MgCl2 (3), K-ATP (2), Na2GTP (0.4), and phosphocreatine (5) at
pH 7.4 and 290 mOsm. Recordings involving inhibitory postsynaptic currents (IPSCs) utilized a
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cesium-based intracellular solution consisting of (in mM): Cs-gluconate (140), HEPES (10),
MgCl2 (3), K-ATP (2), Na2GTP (0.4), and phosphocreatine (5) at pH 7.4 and 290 mOsm.
Whole-cell patches were performed on P-cells in the BLA. P-cells were identified by their
morphology and intrinsic firing properties (Figure 12A). P-cells characteristically display ‘nonadapting’ firing patterns at a moderate frequency while CCK+INs display ‘adapting’ firing patterns
at a much slower frequency (Freund & Katona, 2007; Rainnie et al., 1993). To evoke and
characterize firing patterns, suspected P-cells were patched using the current-clamp technique and
a supra-threshold square-pulse current was injected for three seconds as to elicit and action
potential spike train. For IPSC recordings, P-cells were patched and held at 0 mV using the voltageclamp technique. LED flashes passed through a Texas Red filter, out of the 40x objective, and onto
the slice, inducing IPSCs via optogenetic activation of ReaChR. As ReaChR expression is variable,
LED intensity was adjusted for each cell to ensure baseline IPSCs had a peak amplitude large
enough for pharmacologically-induced changes to be observed, but small enough to avoid
exhausting or damaging tissue. IPSCs protocols were programmed in pCLAMP 10 software and
consisted of stimulation and recording components. A single stimulation (0.1 ms LED application)
occurred 10 ms into a 1000 ms recording window, also called a trace or sweep. Patches in which
sweeps displayed polysynaptic input (multiple peaks) were discarded. Sweeps began every 10 or
15 seconds depending on the individual P-cell’s ability to tolerate and recover from repeat
stimulation and were continuously evoked for 45-60 minutes during pharmacology experiments.
To confirm our recordings were strictly due to GABAergic activity, we performed two
control experiments. A variable holding-potential protocol was used to determine if IPSCs
displayed reversal potential and driving force properties characteristic of chloride. By altering the
voltage-clamp, IPSCs were recorded at different P-cell membrane potentials. In 10 mV increments,
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IPSCs were evoked at holding potentials of 20 mV through -90 mV for a total of twelve sweeps.
After examining reversal potential and driving force, we performed a pharmacological test to
confirm that our postsynaptic currents were produced through GABA binding to the GABAA
receptor. P-cells were held at 0 mV and IPSCs were evoked for several minutes to establish a
baseline peak amplitude. Bicuculline (BIC), a GABAA antagonist, was then added by pipette to
the 60 mL syringe of aCSF. IPSCs were continually evoked until IPSC peak amplitude was
eliminated. After the recording session was finished, the 60 mL syringe, tubing, ground electrode,
40x objective, slice chamber, and harp were washed thoroughly with hydrogen peroxide and
MilliQ water to avoid pre-exposing future tissue to residue from pharmacological agents.
Following confirmation of GABAergic activity, we determined the sensitivity of IPSC peak
amplitude to CaV2.2 block via ω-Conotoxin GVIA (CTX). In the same manner as with BIC, a
baseline IPSC peak amplitude was established under control conditions. Afterwards, CTX was
added to the bath perfusion and sweeps were continually evoked until no further changes in peak
amplitude were observable. At this point, BIC was added to the bath perfusion to demonstrate that
the brain slice was indeed being exposed to pharmacological agents.

Pharmacology
Drug dosing (working concentration) was determined by multiplying the EC50/IC50 of a
given compound by twenty, ensuring full effects would be observable in-perfusion. Stock
concentrations were made at 1000x working concentrations and stored at -20°C. BIC (ab120107;
Abcam) and CGP (ab120167; Abcam), GABAA and GABAB antagonists, respectively, were added
to the bath perfusion (100 µM and 2 µM, respectively) to confirm that IPSCs were due to GABAA
receptor activity. CTX (ab120215; Abcam), a specific CaV2.2 antagonist, was added to the bath

41

perfusion (1 µM) to study the role CaV2.2 in GABA release from CCK+INs onto P-cells in the
BLA. Of note, we later determined that 1 µM CTX was a much higher dose than required.
Equivalent effects were observable using 300 nM, and we used this dose in future experiments
(CHAPTERS 2/3). Smaller lipophilic compounds took considerably less time to display full
effects on peak amplitude compared to larger lipophobic compounds. BIC permeated the slice and
blocked IPSCs typically within five minutes, whereas CTX typically took fifteen minutes.

Data Analysis
After electrophysiology experiments were recorded, IPSC data was analyzed in Clampfit
software and plotted in Origin 6.1 (OriginLab). Sweeps were selected to represent the changes that
occurred to IPSCs under various holding voltages and pharmacological conditions. For
pharmacological studies, we used IPSC peak amplitude (in pA) as a quantitative measure of the
amount of GABA released from CCK+INs onto P-cells. Peak amplitudes were calculated by
subtracting baseline sweep current (pre-IPSC) from the maximum positive-going current of the
sweep, which occurred just milliseconds after LED stimulation. The time at which each sweep
began was converted into minutes, to create a timescale. For recordings in which sweeps occurred
in 15 second intervals, sweep 1 = 0 min, sweep 2 = 0.25 min, sweep 3 = 0.5 min, etc. The peak
amplitude and time values for each sweep were plotted in Origin 6.1. A time-course line plot was
created from this data for each cellular recording (n = 7). IPSC peak amplitude (pA) was assigned
to the y-axis and time (min) to the x-axis.
A two-point segment graph was created to compare mean IPSC peak amplitude under
control and CTX conditions across multiple cells (Figure 13 - bottom right). Recordings from
male and female CCK-Dlx5/6-ReaChR mice were pooled in this plot, as there was no significant
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association between sex and CTX effects (see details in results). The mean control conditions IPSC
peak amplitude was calculated by averaging peak amplitude values from sweeps prior to CTX
addition to the bath perfusion. CTX-dependent effects were examined only after the point in the
time-course plot at which peak amplitude no longer decreased, i.e. the ‘plateau’ phase. From this
time point forward, peak amplitudes across sweeps were averaged to obtain the mean peak
amplitude under CTX conditions. For within-animal analysis, a one-tailed paired t-Test was
performed in Microsoft Excel 2016 to determine if there was a significance to the changes in peak
amplitude when moving from control to CTX conditions. For cross-animal analysis, control and
CTX condition peak amplitudes were averaged for the seven recordings and plotted as grey circles
in the two-point segment plot. The standard deviation (SD) and standard error of the mean (SEM)
were calculated for both conditions as both numerical values (in pA) and percentages. Vertical
black bars attached to the gray average peak amplitude circles on the two-point segment plot
represent the SEM (in pA).

Results
Histological Characterization in CCK-tdT and CCK-Dlx5/6-tdT Mice
Fluorescence experiments in CCK-tdT mice labelled CCK+ cell/tissues with tdTomato and
cell bodies with SYTO-13 (Figure 10A). Confocal microscopy images display widespread CCK
expression with notable regions of concentrated signal. CCK fluorescence is particularly intense
in the BLA, layer 2 of the piriform area, the piriform-amygdalar area, and the endopiriform nucleus
(Figure 10A - left). CCK expression is weak in the CeA and layer 1 of the piriform area. Like
CCK, SYTO-13 signaling is also low in the thalamus and layer 1 of the piriform area, as well as
the external capsule (Figure 10A - middle). Colocalization of CCK and SYTO-13 signal,
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represented by yellow fluorescence, indicates a CCK+ cell (Figure 10A - right). Groups of CCK+
cells appear in the medial portion of the BLA, the LA, and the dorsal endopiriform nucleus.
Fluorescence experiments in CCK-Dlx5/6-tdT mice labelled CCK+INs with tdTomato and
cell bodies with SYTO-13 (Figure 10B). Confocal images show that tdTomato expression is
restricted to a fewer number of cells than in the CCK-tdT mouse. CCK+ signaling is constrained
to GABAergic INs and their projections. Cell bodies strongly express tdTomato while expression
in what appear to be neuronal projections is much milder and variable. Based on morphology,
thicker projections (i.e. primary dendrites) can contain more CCK expression and higher levels of
fluorescence than thinner projections (i.e. secondary/tertiary dendrites). Thin, faint networks of
CCK+ projections can be seen in the center of the BLA. CCK+INs are mostly absent in the external
and amygdalar capsules but are prevalent in the ventral/dorsal endopiriform nucleus and the BLA
(Figure 10B - left). SYTO-13 signaling appears prevalent and uniform in the BLA, absent in the
external/amygdalar capsules, and sparse in the ventral endopiriform nucleus (Figure 10B - middle).
Since CCK-Dlx5/6-tdT mice possess the Dlx5/6 promotor, colocalization of CCK and SYTO-13
signal is indicative of GABAergic CCK+INs (Figure 10B - right). Compared to the CCK-tdT
mouse (Figure 10A - right), there is very little colocalization signal in the CCK-Dlx5/6-tdT model.
Colocalization distribution appears more uniform however, and the clustering of highly
concentrated yellow signal in Figure 10A - left is not present. Web-like tdTomato signaling
(Figure 10B - left) surrounds cell bodies (Figure 10B - right), a characteristic pattern of
perisomatic inhibitory networks.
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Figure 10| CCK expression in CCK-tdT mice and GABAergic CCK expression in CCK-Dlx5/6-tdT

mice. A| Fluorescence images of coronal brain slices containing the BLA from an adult CCK-tdT mouse
(10x magnification). Left: tdTomato (red) is expressed in all CCK+ cells/tissue. Middle: SYTO-13 nucleic
acid stain (green) labels cell bodies. Right: In an overlay of the two channels, cell bodies that express CCK
appear yellow due to colocalization of SYTO-13 and tdTomato signal. B| Fluorescence images of coronal
brain slices containing the BLA from an adult CCK-Dlx5/6-tdT mouse (20x magnification). Left:
Cells/tissue that contain both CCK+ and Dlx5/6 promoters express tdTomato. Middle: Cells bodies are
stained with SYTO-13. Right: In an overlay of the two channels, CCK+INs appear yellow due to
colocalization of tdTomato and SYTO-13 signal.

Characterization of Fluorescence in CCK-ChR2 and CCK-Dlx5/6-ReaChR Mice
CCK-ChR2 mice express EYFP-tagged ChR2 in CCK+ cells/tissue (Figure 11A). The
BLA, CeA, and cortical tissue display weak EYFP signaling while the piriform area and the
endopiriform nucleus display stronger signaling (Figure 11A - left). At 40x magnification, ChR2
expression is absent in what appear to be cell bodies and blood vessels (Figure 11A - right).
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Overall fluorescence levels are moderate, but strong EYFP signaling in what morphologically
appear to be neuronal projections can be distinguished from the background in the lower righthand side of Figure 11A - right. Focusing on the small bulbous structures containing strong EYFP
signal throughout the tissue, it looks as if ChR2 is expressed in CCK+ synaptic terminals.
CCK-Dlx5/6-ReaChR mice express mCitrine-tagged ReaChR in CCK+INs. Confocal
images of fluorescence in these mice contain strikingly specific and distinguishable mCitrine
expression (Figure 11B - left). Since ReaChR expression is confined to GABAergic CCK+INs,
cell and their projections are far easier to distinguish from the background than in Figure 11A right. ReaChR is embedded in the transmembrane domain and fluorescence is restricted to the Cterminus of these cation channels, thus mCitrine signal is not as robust as tdTomato signal under
the microscopy conditions that we used for imaging. Based on morphology, the thin, rod-like
projections with high fluorescence could represent ReaChR in CCK+IN dendrites while the small,
bulbous areas of high fluorescence could represent ReaChR in CCK+IN synaptic terminals
(Figure 11B - right). Some CCK-negative cells, represented by empty/black circles, appear to be
isolated from CCK+IN innervation in the lower right-hand side of Figure 11B - left. Other CCKnegative cells are surrounded by mCitrine fluorescence in what appear to be patterns of perisomatic
inhibition by CCK+INs (Figure 11B - left). A CCK+IN with extensive ReaChR expression is
observable in Figure 11B - right along with its highly-fluorescent projections.
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Figure 11| Channelrhodopsin expression in the BLA of CCK-ChR2 and CCK-Dlx5/6-ReaChR mice.
A| Confocal images of
fluorescence in coronal brain
slices containing the BLA
from an adult CCK-ChR2
mouse. EYFP (yellow) is
bound to the C-terminus of
channelrhodopsin-2
and
expressed
in
CCK+
cells/tissue. Left: Widespread
EYFP expression can be seen
in and around the BLA. Right:
EYFP can be seen in what
appear to be dendrites and
synaptic terminals, but not in
cell bodies. B| Confocal
images of fluorescence in
coronal brain slices containing
the BLA from an adult CCKDlx5/6-ReaChR
mouse.
mCitrine (yellow) is bound to
the C-terminus of Redactivatable channelrhodopsin
(ReaChR) and expressed in
GABAergic CCK+INs. Left:
Non-fluorescent cell bodies
are heavily innervated by
ReaChR-mCitrine, indicating
postsynaptic currents can be
recorded from these cells using
optogenetics. Right: ReaChR
can be seen in a CCK+IN and
its projections. Some surrounding cells are innervated by the CCK+IN in patterns characteristic of
perisomatic inhibition, while others receive no innervation.

Light-evoked IPSCs in CCK+IN/P-cell Synapses in the BLA
The BLA (Figure 12A - left) contains P-cells with piriform morphology and projections
on their apical and basal ends (red circle in Figure 12A - middle). P-cell displayed non-adapting
firing patterns when stimulated by a supra-threshold square-pulse current injection (Figure 12A right). When P-cells were held at 0 mV, a positive-going inhibitory postsynaptic current (IPSC)
was produced (black trace in Figure 12B - left). The driving force for Cl- was strong and inwards
when the membrane potential was clamped at 0 mV (the equilibrium potential for chloride is -70
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mV). When P-cells were held at -70 mV, there was no IPSC following optogenetic stimulation, as
there was no driving force for Cl- at this membrane potential (mint trace in Figure 12B - left).
When P-cells were held at -90 mV, a negative-going reverse IPSC was produced (purple trace in
Figure 12B - left). At this membrane potential, the driving force for Cl- was small and outwards,
into the extracellular space. Exposing P-cells to BIC lead to an elimination of control-condition
IPSCs (Figure 12B - middle). BIC swiftly, totally, and irreversibly blocked optogeneticallyevoked IPSCs in CCK+IN/P-cell synapses in the BLA of CCK-Dlx5/6-ReaChR mice (Figure 12B
- right).

Figure 12| Morphophysiology and postsynaptic currents in CCK+IN/P-cell synapses in the BLA.
Scale bars represent size in DIC images and time/current in IPSC traces. A| Identifying P-cells in the BLA
of adult CCK-Dlx5/6-ReaChR mice. Left: DIC microscopy of the BLA contained in the brain slice chamber
(4x magnification). Middle: Micropipette performing a whole-cell patch on a P-cell in the BLA (red circle).

48

Distinct piriform morphology and projections are observable. Right: A non-adapting firing pattern
characteristic of P-cell intrinsic firing properties was produced by a supra-threshold square-pulse current
injection. B| Confirming GABAergic activity of IPSC in CCK+IN/P-cell synapses. Left: IPSCs evoked at
variable holding potentials display patterns representative of the driving force of Cl-. A positive-going peak
is produced when the P-cell is held at 0 mV (top, black). No peak is produced at -70 mV (middle, mint),
and a negative-going peak is produced at -90 mV (bottom, purple). Middle: IPSC traces under control and
bicuculline (BIC) conditions. BIC (100 µM) eliminates IPSCs. Right: Time-course plot of IPSC peak
amplitude under control and BIC conditions (indicated in the color-coded timeline). BIC added to the bath
perfusion after 3 min rapidly eliminates IPSCs. Peaks are initially 400 pA and reduce to <10 pA after 8 min.
There is no IPSC recovery upon continued stimulation.

Cav2.2 Block Reduced IPSC Peak Amplitude in CCK+IN/P-Cell Synapses in the BLA
CTX reduced IPSC peak amplitude in CCK+IN/P-cell synapses in the BLA of CCKDlx5/6-ReaChR mice (Figure 13 - top right). A cellular recording is represented in a time-course
plot wherein average IPSC peak amplitude drops from 230 pA to 66 pA following CTX conditions
(Figure 13 - left). It took about fifteen minutes for CTX to decrease peak amplitude to a new stable
baseline, and five additional minutes for BIC to eliminate the remaining IPSCs (Figure 13 - left).
These two drugs have different pharmacokinetics and pharmacodynamics, thus permeate the slice
and act upon their targets at different rates. A total of seven cells were treated with CTX and their
average peak amplitudes under control and CTX conditions are represented in a two-point segment
plot (Figure 13 - bottom right). Each pair of circles represents the average IPSC peak amplitude
before and after CTX treatment for one cellular recording. Comparisons across cells were made
by calculating the percentage change in IPSC peak amplitude for each recording. The mean IPSC
peak amplitude decrease for all seven cells was 51% (SD = 14%, SEM= 7%), with an average
amplitude of 211 pA (SD = 103 pA, SEM = 39 pA) under control conditions and 97 pA (SD = 40
pA, SEM = 15 pA) under CTX conditions. There was no association between sex and CTX effects
(51.87% mean peak amplitude decrease for males vs. 49.56% for females). A one-tailed paired tTest on average control and CTX peak amplitudes produces a p-value of 0.0046. We conclude that
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there was a significant effect of CTX on IPSC peak amplitude, and that GABA release from
CCK+INs in the BLA is partially CaV2.2-dependent.

Figure 13| CaV2.2 antagonism reduces IPSC peak amplitude in CCK+IN/P-cell synapses in the BLA.
Optogenetically-evoked IPSC were recorded in adult CCK-Dlx5/6-ReaChR brain slices. Left: Time-course
plot of IPSC peak amplitude under three pharmacological conditions (indicated in color-coded timeline).
w-Conotoxin GVIA (CTX, 1 µM) and bicuculline (BIC, 100 µM) were added to the bath perfusion at 30
and 49 min, respectively. Peak amplitude was initially 230 pA but reduced to 66 pA following CTX addition.
Blockade stabilized at 41 mins. BIC addition eliminated remaining IPSCs. Top right: Representative IPSCs
traces from each of the three pharmacological conditions. The top IPSC (black) is a control trace. The
middle (red) and bottom (blue) IPSCs are traces under CTX and BIC conditions, respectively. Scale bars
represent time and current values. Bottom right: Two-point segment plot of average IPSC peak amplitude
under control and CTX conditions for multiple recordings. Each pair of circles represents one cell (n = 7).
CTX significantly decreased peak amplitude (p = 0.0046, one-tailed paired t-Test) by an average of 51%
compared to control conditions (SD = 14%, SEM = 5%). Grey circles represent the mean IPSC peak under
control (211 pA) and CTX (97 pA) conditions. Vertical black lines represent the SEM (39 pA and 15 pA,
respectively).
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Discussion
Connections between CCK+INs and P-cells have been described in the cerebral cortex
(Freund, 2003), hippocampus (Whissell et al., 2015), and amygdala (Andrási et al., 2017; Freund
& Katona, 2007). Additionally, the role of CaV2.2 in CCK+IN/P-cell synapses has been described
for the hippocampus (Szabo et al., 2014). This is the first study to demonstrate the role of CaV2.2
in CCK+IN/P-cell synapses in the BLA. GABA release from CCK+INs onto P-cells in the CA3
region of the hippocampus was shown to be entirely blocked by CTX (Szabo et al., 2014). We
found that in the BLA, GABA release is only partially blocked (51%). Our findings suggest that
CCK+IN/P-cell are functionally distinct in the BLA and the hippocampus.

Specificity of CCK-Dlx5/6-ReaChR Mouse Model
Optogenetics allows for a level of precision in circuit-level research unattainable with
traditional methods like electrical stimulation (Tye & Deisseroth, 2012). Electrical stimulation is
a longstanding means of inducing neurotransmitter release and studying neurophysiology. While
there are many appropriate applications of electrical stimulation, it is impractical to try to isolate
specific cell circuitry using this technique. Investigations are limited because electrical stimulation
excites all of the cells in proximity of the microelectrode. Accordingly, postsynaptic currents are
the result of cumulative neurotransmitter release from multiple inputs, some of which may not be
the target of study. Optogenetic stimulation induces transmitter release by opening light-gated ion
channels and depolarizing the membrane of a genetically targeted neuronal population, thus the
power of optogenetics lies in its cell specificity.
Critical to our research interests, genetic targeting of GABAergic INs has been made
possible in recent years. Taniguchi and colleagues (2011) used Cck-IRES-Cre, Dlx5/6-Flp, and dual
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recombinase-expressing mice to label GABAergic CCK+INs with GFP. Our CCK-Dlx5/6-tdT
mouse model followed similar intersectional breeding framework, and as a result we are confident
in our specific labelling of CCK+INs with tdTomato. Also critical to our research interests,
optogenetic techniques have successfully been used to study perisomatic inhibitory circuits in the
amygdala. Andrási and colleagues (2017) present electrophysiological data demonstrating potent
inhibition of P-cells by local CCK+INs, as well as ChR2-mediated excitation of P-cells.
Accordingly, our CCK-Dlx5/6-ReaChR mouse model aligns with prior models and can be used to
make conclusions regarding CCK+IN/P-cell neurophysiology in the BLA.

Expression of tdTomato and ChR in CCK+ Cells in the BLA
Confocal microscopy images of fluorescence in CCK-tdT mice demonstrate widespread
tdTomato expression throughout the brain slice (Figure 10A - left). This is to be expected, as the
amygdala and surrounding cortical regions are known to contain high levels of CCK, both as a
marker for excitatory and inhibitory cells (Beinfeld, Meyer, Eskay, Jensen, & Brownstein, 1981).
Accordingly, the widespread expression of ChR2 in CCK+ cells from CCK-ChR2 mice is also to
be expected (Figure 11A). We observe similar patterns of tdTomato and EYFP fluorescence in
CCK+ cells (Figure 10A/11A - left). Of note, the structures with intense fluorescence are related
to the limbic system. Fluorescence is particularly concentrated in the LA and medial BLA, as well
as the cortical piriform area, the piriform-amygdalar area, and the endopiriform nucleus. The latter
three brain areas are part of the piriform cortex, a structure which is thought to be implicated in
olfactory-based learning (Krettek & Price, 1977; Majak, Pikkarainen, Kemppainen, Jolkkonen, &
Pitkänen, 2002). High expression of CCK+ cells has been reported in the piriform-amygdalar area
and the endopiriform nucleus previously (Ingram, Krause, Baldino, Skeen, & Lewis, 1989). The
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role of CCK in olfactory structures has been identified (Ma et al., 2013), and it continues to be a
neurotransmitter of interest for sensory-limbic integration. Therefore, our observations of CCK
expression and tdTomato/EYFP fluorescence in CCK-tdT and CCK-ChR2 mice support previous
findings.
Fluorescence experiments in CCK-Dlx5/6-tdT mice illustrate that CCK expression is far
more refined when restricted to GABAergic IN populations (Figure 10B - left vs Figure 10A left). Additionally, there are far fewer light-gated ion channel expressed in CCK-Dlx5/6-ReaChR
mice (Figure 11B - right) when compared to CCK-ChR2 mice (Figure 11A - right). By
incorporating Dlx5/6-Flpe into our CCK-Dlx5/6-tdT and CCK-Dlx5/6-ReaChR triple transgenic
mouse models, tdTomato/mCitrine fluorescence is only expressed in GABAergic CCK+INs
(Taniguchi et al., 2011). As described by Freund (2007), CCK+IN innervation exerts heavy control
over P-cells the BLA. This innervation appears to be isolated in both triple transgenic mouse
models and visualized in Figure 10B - left and Figure 11B - right. CCK+INs sit atop web-like
patterns of low-level tdTomato fluorescence (Figure 10B - left) and mCitrine fluorescence
encircles empty cell bodies (Figure 11B - right). Both patterns likely indicate perisomatic
inhibitory connections with local P-cells. Strikingly similar images are presented by RoviraEsteban and colleagues (2017), who selectively targeted GABAergic CCK+INs using a BACCCK-DsRed mouse line (adapted from Máté et al., 2013). These patterns are not observable in
CCK-tdT mice (Figure 10A) or CCK-ChR2 mice (Figure 11A), as glutamatergic and GABAergic
CCK+ expression are homogenized in these lines.

GABA Release from CCK+INs onto P-cells in the BLA is Partially CaV2.2-dependent
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When analyzing neurotransmitter release, IPSCs are a useful quantitative measurement as
they allow for direct insight into fast-synaptic activity. The amplitude of an IPSC is reflective of
the degree of inward anion (Cl-) flow, which is the product of GABA binding to GABA receptors.
Greater amounts of neurotransmitter binding will produce stronger IPSCs with higher peak
amplitudes. Reduced neurotransmitter binding will produce weaker IPSCs with lower peak
amplitudes.
We observe decreases in IPSC peak amplitude following CTX addition in all patch-clamp
recordings (Figure 13 - bottom right). This consistency suggests that CaV2.2-dependent GABA
release from CCK+INs is pervasive and present to some degree around most P-cells in the BLA.
While pervasive, it does not appear uniform. Neither total IPSC block nor zero IPSC block was
observed in any of our recordings; decreases in peak amplitude ranged from 32% to 71%. There
is likely variation in the degree to which CaV2.2 is expressed in presynaptic CCK+IN terminals.
The remaining peak amplitude suggests that there are additional CaV2 subtypes which mediating
neurotransmitter release. P/Q-type channels facilitate GABA release from PV+INs onto P-cells,
and CCK+INs are closely paired with PV+INs in perisomatic inhibitory circuits (Sparta et al.,
2014; Zamponi & Currie, 2013). Accordingly, P/Q-type channels may also play a role in
transmitter release from CCK+IN terminals in the BLA. It has been demonstrated previously that
there is a degree of functional compensation between P/Q-type channels and N-type channels in
the presynaptic terminal (Inchauspe, 2004). Another possible CaV2 subtype, the R-type calcium
channel, has been shown to partially contribute to action potentiation in presynaptic P-cell inputs
(Wu, Borst, & Sakmann, 1998). R-type blockers (i.e. Lamictal) are used as mood-stabilizing drugs
and in the treatment of affective disorders (Zamponi, 2016), thus may have some role in anxietyrelated neuronal output from the BLA. As the functional roles of many presynaptic calcium
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channels in regulating neurotransmitter release across brain regions remain unidentified, further
pharmacological testing is required to determine which CaV subtypes regulate GABA release in
CCK+IN/P-cell synapses in the BLA.
Observations of partial CaV2.2-dependency in CCK+IN/P-cell synapses suggest that
CaV2.2 differentially regulates neurotransmitter release in the BLA compared to other brain
regions. Szabó and colleagues (2014) report complete IPSC blockade in response to CTX (i.e. total
CaV2.2-dependency) in CCK+IN/P-cell synapses in the hippocampus (CA3). Partial reduction of
IPSC peak amplitude in the BLA is not likely due to of insufficient CTX dosing. Szabó and
colleagues (2014) saw complete block with a 50 nM dose while we used 1 µM. Moreover, we
incrementally increased CTX concentration after decreases in IPSC peak amplitude had plateaued
and no further effects were observable (Figure 13 - left).
Overall, our findings are an important contribution to the growing understanding of the
molecular mechanisms involved in anxiety. We demonstrate that although CCK+IN/P-cell
synapses are also found in the HPC and PFC, these circuits are differentially regulated by CaV2.2
in the BLA. Additionally, our results challenge the notion that CaV2.2 is the only CaV2 subtype
involved in regulating neurotransmitter release from CCK+INs. These two concepts are important
when considering the conflicting anxiogenic and anxiolytic properties reportedly caused by CaV2.2
antagonists. Anxiety-related neuronal activity and ultimately the experience of anxiety-like
symptoms are likely differentially modulated by CaV2.2 in different brain regions. As a result,
novel CaV2.2-based pharmacological treatments for anxiety disorders should consider regionspecific effects and target precise anxiogenic circuits.
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Additional Considerations for Future Research
CaV2.2 blockade partially reduced IPSC peak amplitude in CCK+IN/P-cell synapses in the
BLA. By blocking additional CaVs, we may be able to determine which additional subtypes are
behind the remaining peak amplitude. Following a similar electrophysiology protocol, additional
CaV antagonists could be added to the bath perfusion following ω-Conotoxin GVIA. There are
pharmacological agents that specifically target other CaV subtypes; Nimodipine is an L-type
blocker, ω-Agatoxin IVA is a P/Q-type blocker, and SNX 482 is an R-type blocker. By blocking
CaV subtypes in succession, we can fully eliminate IPSCs. If this process of multiple drug
conditions prolongs recordings to the point at which they become detrimental to slice health,
multichannel blockers could be used instead. Drugs like cilnidipine (N- and L-type blocker) or ωConotoxin MVIIC (N- and P/Q-type blocker) may eliminate IPSCs in our system.
The CCK-Dlx5/6-ReaChR mouse model we have developed has incredible potential for
studying CCK+INs. These studies do not have to be limited to circuits in the BLA, or even to
electrophysiology experiments. ReaChR has been shown to enable transcranial optogenetic
activation of neurons in deep brain structures (Lin et al., 2013). Therefore, the role of CCK+INs
in behavior could be examined. Local injections, toxins, and other genetic manipulations would
allow us to target the underlying components behind CCK+IN-related behaviors. Fluorescence
experiments in our CCK-Dlx5/6-tdT mouse line have shown extensive CCK+IN expression
throughout the brain and spinal cord. There are major CCK+IN-mediated properties left
unexplored at the behavioral and cellular level. For example, CCK+INs have been shown to
innervate other CCK+INs, parvalbumin-expressing basket cells (PV+BCs), and even themselves
via autapses (Freund, 2003; Fukudome et al., 2004; Rainnie et al., 1993). We have demonstrated
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that we can distinguish between P-cells and INs in patch-clamp recordings; additional research
could study the role of CaV2.2 in CCK+IN/CCK+IN synapses.
In addition to CCK+INs, PV+INs synapse onto the soma of P-cells to form a system of
perisomatic inhibition. This type of inhibition has been well studied in the hippocampus and
cerebral cortex (Freund, 2003), however less is known about its role in the BLA. PV+INs have
firing properties distinct from CCK+INs, indicating they process inputs differently. PV+INs fire
fast non-adapting spiking patterns, allowing them to process multiple converging stimuli (Bartos
& Elgueta, 2012). Despite the relevance of spiking frequencies on PV+IN function, the ion channel
composition underlying these distinctive properties has not been fully described in the BLA.
Spiking frequency depends on the concerted activity of various ion channels, including CaVs and
calcium-activated potassium channels (KCas). Generally, CaVs provide calcium for the activation
of KCas; a form of selective coupling that then hyperpolarizes neurons and reduces spiking
frequency (Womack, 2004). In the future, we can propose a comprehensive study that combines
in vitro electrophysiology, transgenic mouse models, and pharmacology to compare CaVs and KCas
in CCK+INs and PV+INs in the BLA, to determine which channels underlie higher spiking
frequency patterns in PV+INs.
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CHAPTER 2: CB1-MEDIATED MODULATION OF GABA RELEASE FROM CCK+
INTERNEURONS ONTO PYRAMIDAL CELLS IN THE BASOLATERAL AMYGDALA
Abstract
The endocannabinoid (eCB) system is a network of receptors and ligands throughout the
mammalian brain implicated in anxiety. The type-1 cannabinoid receptor (CB1) is expressed at
high levels in the basolateral amygdala (BLA), a brain region involved in regulating anxiety-like
behaviors. The BLA is the main source of excitatory neuronal output from the amygdala to brain
regions like the prefrontal cortex and hippocampus. This output is facilitated by pyramidal cells
(P-cells) and regulated by local inhibitory interneurons (INs). INs that express the neuropeptide
cholecystokinin (CCK+) are known to co-express CB1. CB1 regulates neurotransmitter release
from CCK+INs by downregulating voltage-gated calcium channels (CaVs) in the presynaptic
terminal. P-cells disinhibition in the BLA may contribute to increased anxiety-like behaviors. CB1mediated inhibition can occur in a ligand-dependent (phasic) and ligand-independent (tonic)
manner. It has been demonstrated that CB1 is expressed in CCK+INs in the BLA, however the
underlying molecular mechanisms of these channels is not well understood. Using a combination
of transgenic mouse models, immunofluorescence, electrophysiology, and pharmacology, we
aimed to determine if/how CB1 modulates CCK+IN/P-cell synapses in the BLA. Our confocal
microscopy experiments revealed heavy colocalization of CB1 and CCK+IN signal in both the
BLA and hippocampus. Using optogenetic stimulation and whole-cell patch clamp
electrophysiology in our transgenic mouse model (CCK-Dlx5/6-ReaChR), we evoked GABA
release from CCK+INs and recorded inhibitory postsynaptic currents (IPSCs) in P-cells. We then
determined how sensitive GABA release was to CB1 modulation by observing IPSC peak
amplitude under control condition and following bath addition of a CB1-agonist (2-AG) and a CB1antagonist (AM251). Our initial recordings suggests there is both phasic and tonic CB1-mediated
inhibition of GABA release from CCK+INs in the BLA. IPSC peak amplitude decreased by 26%
from control to 2-AG conditions and increased by 34% from control to AM251 conditions.
Following the publication of a comprehensive study on CCK/CB1-expressing INs in the BLA by
Rovira-Esteban and colleagues (2017), we decided to discontinue electrophysiology recordings
and reallocate our mice to focus on novel experiments. Our preliminary data serves to confirm the
findings presented by Rovira-Esteban and colleagues (2017), and our model transgenic mouse
model serves as a tool for future studies on the molecular components underlying CB1-mediated
inhibition in the BLA.
Introduction
The endocannabinoid (eCB) system is a series of ligands and receptors integral for
regulating synaptic transmission in brain areas like the prefrontal cortex (PFC), hippocampus
(HPC), and basolateral amygdala (BLA). Circuit-level modulation of the eCB system can have
large impacts on emotion and behavior, particularly in areas involved in anxiety (Lutz et al., 2015).
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In the brain regions implicated in anxiety, type-1 cannabinoid receptors (CB1) are located in
presynaptic terminals. CB1 is activated by the eCBs 2-Arachidonoylglycerol (2-AG) and
anandamide (AEA), as well as exogenous cannabinoids (CBs) like tetrahydrocannabinol (THC)
and cannabidiol (CBD) (Katona et al., 2001; Lee et al., 2015). Upon eCB/CB binding, CB1
downregulates voltage-gated calcium channels (CaVs), preventing calcium entry, vesicular fusion,
and neurotransmitter release (Guo & Ikeda, 2004). CB1 is believed to target and couple with CaV2
channels, as they are also transmembrane proteins located in the presynaptic terminal (Alger, 2002;
Wilson et al., 2001). CB1 and CaV2 are present in the excitatory cortical inputs to the amygdala
(via the external capsule), and in inhibitory inputs from local INs (Azad, 2003). Dual expression
in excitatory and inhibitory inputs suggests that eCBs can modulate output from the BLA and
subsequently anxiety-related behaviors (Katona et al., 2001; Patel, Kingsley, MacKie, Marnett, &
Winder, 2009; Yoshida et al., 2011). Additionally, it has been proposed that by acting with the eCB
system, cholecystokinin-containing (CCK+) interneurons (INs) modulate fear inhibition and
extinction (Bowers et al., 2012).
CB1 is selectively expressed in CCK+INs over other IN subtypes in the hippocampus
(Katona et al., 2001). CCK+INs are known to regulate glutamatergic signaling of local pyramidal
cells (P-cells), and are found in the neuronal output circuits of brain areas like the BLA, ventral
HPC, and medial PFC (Freund & Katona, 2007). CCK+IN synapses can undergo CB1-mediated
depolarization-induced suppression of inhibition (DSI), a form of phasic, short-term inhibition
(Zhu, 2005), as well as eCB-mediated long-term depression (LTD), a form of tonic, CB1independent inhibition (Marsicano et al., 2002). Both DSI and LTD are necessary for fear
extinction (Chhatwal et al., 2009), a behavioral response facilitated by reciprocal connections from
the infralimic cortex (IL) of the medial PFC to the BLA (Sierra-Mercado et al., 2011). In the BLA,
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CB1 expression is found in the CCK+INs involved in perisomatic inhibition (basket cells (BCs))
(Mascagni & McDonald, 2003). These CCK+INs can be further grouped according to their level
of CB1 expression; so-called ‘high CB1-expressing’ CCK+INs are sparsely distributed while ‘low
CB1-expressing’ CCK+INs are more evenly-distributed (Marsicano & Lutz, 1999; Yoshida et al.,
2011).
While eCBs and CB1 have been shown to modulate CCK+INs in multiple brain areas
(Chhatwal et al., 2009; Szabo et al., 2014), the mechanisms by which they modulate
neurotransmitter release and CaVs is not completely understood (Lozovaya, Min, Tsintsadze, &
Burnashev, 2009). N-type CaVs (CaV2.2) and CB1 are localized in CCK+INs and often found in
regulatory nanodomains, indicating they have a strong functional linking (Dudok et al., 2015).
Studies have revealed complex regulatory roles of CB1 and eCBs on CaV2.2 in the HPC. Lenkey
and colleagues (2015) observed that in the CA3 region of the HPC, tonic eCB-mediated activation
in CCK+INs resulted in reduced Ca2+ entry through CaV2.2, independent of CB1 content. Lenkey
and colleagues (2015) also observed that only the CB1 receptors located within 1 nm of Cav2.2
were responsible for eCB-mediated modulation of GABA release (Lenkey et al., 2015).
Additionally, CCK+INs in the CA1 region of the HPC were reported to experience CB1-mediated
tonic inhibition of GABA release, disrupting perisomatic inhibition networks (Neu et al., 2007).
It is not known whether the eCB-dependent and eCB-independent mechanisms observed
in the HPC are conserved in CCK+INs in the BLA. If conserved, CB1 may modulate anxiety at
the level of the BLA, indicating eCBs, CB1, and CaV2.2 can possibly be targets of neuromodulators
with anxiolytic properties. In this study, we aim to visualize CB1 receptors in CCK+INs of the
BLA and characterize their inhibition (phasic and/or tonic) of P-cells. If present, we aim to
determine how CaV2.2 modulates eCB-mediated inhibition. We expect our experiments will reveal
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more information on the contribution of eCBs and CB1 to neurotransmitter release in CCK+IN/Pcell synapses in the BLA, which can be used to compare the role of CB1 between the HPC and
BLA.

Methods
Animal Models
Refer to CHAPTER 1 for detailed information on the breeding, background, and research
applications of our CCK-Dlx5/6-tdT and CCK-Dlx5/6-ReaChR mouse models. CCK-Dlx5/6-tdT
mice were used in immunofluorescence experiments to visualize CCK+IN and CB1 expression
and colocalization in the BLA and HPC. CCK-Dlx5/6-ReaChR mice were used in
electrophysiology experiments to study the role of CB1 in CCK+IN/P-cell synapses in the BLA.

Immunofluorescence
Adult CCK-Dlx5/6-tdT mice were deeply anesthetized with isoflurane (07-893-1389;
Patterson Veterinary) and given an intraperitoneal injection of Euthasol euthanasia solution
(710101; Virbac Co.). Whole animal perfusion fixations were performed using formalin solution
(HT501128; Sigma-Aldrich). Brains were rapidly dissected and stored at 4°C in formalin solution
for 24-72 hours for further fixation. 80-100 µm coronal brain slices containing the amygdala and
hippocampus were prepared using a vibratome (VT1000 S; Leica) and transferred to a 12-well
plate (Greiner Bio-One). Slices were gently washed once in PBS and twice in 1% PBT (1% Triton
X (T8787; Sigma-Aldrich) in PBS (P3813; Sigma-Aldrich)) for 10 minutes per wash on an orbital
rocker (SK-O180-S; Scilogex). Slices were blocked in a 5% bovine serum albumin/PBT (5%
BSA/PBT) solution for two hours at room temperature. After blocking, slices were washed three
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times in 1% PBT before primary antibody incubation in a 1:200 dilution of anti-CB1 antibody
(ab23703; Abcam) and 5% BSA/PBT for 24-36 hours at 4°C. Following primary antibody
incubation, slices were washed three times in 1% PBT and incubated in goat anti-rabbit Alexa 488
(ab150077; Abcam) secondary antibody for four hours at room temperature. After secondary
antibody staining, slices were washed twice in 1% PBT and once in PBS before mounting onto
micro slides (48311-703; VWR) with Vectashield medium (H-1400; Vector Laboratories) and
micro cover glass (48393-221; VWR). Slides were stored at 4°C for a minimum of 24 hours before
confocal imaging.

Confocal Imaging and Colocalization Quantification
Confocal microscopy on immunostained brain slices was completed using a Zeiss LSM
510 Meta. Multi-track acquisition with argon and helium-neon lasers was used to acquire images
without excitation cross-talk. A series of band- and long-pass filters were applied to capture
isolated emission peaks from individual fluorophores and prevent emission cross-talk.
Fluorophores and their spectra (excitation/emission (nm)) were Alexa 488 (490/525) and tdTomato
(554/581). Images were set to either a 1024 x 1024 or 2048 x 2048 frame size. A left-to-right scan
with line averaging was used, each line being scanned eight times. The camera pinhole was kept
at 1 airy unit across all imaging. Range indication was used to adjust the amplifier offset and
detector gain, preventing over/under saturation of signals. A combination of tile-scans, z-scans,
and single-plane images were taken at 5x, 10x, 20x, 40x, and 63x.
CB1/CCK colocalization analysis was conducted with Carl Zeiss LSM Software (version
3.2). Single plane images of the BLA and the HPC were taken in the same brain slice using
identical amplifier offset and detector gain settings to standardize fluorescence intensity. Intensity
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thresholds were set using two different methods. First, intensity thresholds were manually set for
green and red channels as to only include fluorescence in cell bodies/neuronal processes and
exclude background signal. Second, intensity thresholds were automatically set using the Costes
automated method, which computes the average intensity and standard deviation based off of a
background ROI (an unlabeled cell body without observable CCK/CB1 innervation). Of the two
intensity threshold methods, our colocalization calculations were based off the Costes automated
method as to prevent experimenter biases in threshold selection. Colocalization cut masks images
were produced using this threshold in which only pixels containing colocalized CCK and CB1
expression are displayed. The Mander’s unweighted colocalization coefficient (MCC) and
Pearson’s correlation coefficient (PCC) were used to quantify colocalization and generated using
the Costes automated method.

Electrophysiology
Refer to CHAPTER 1 for specific details on in vitro brain slice preparation and
electrophysiology, as we applied the same protocols up to the point of pharmacological additions.
Briefly, whole-cell voltage-clamp electrophysiology was performed on P-cells in the BLA of an
adult CCK-Dlx5/6-ReaChR female. GABA release was evoked from CCK+INs every fifteen
seconds through optogenetic stimulation of ReaChR channels and IPSCs were recorded in
proximal P-cells. A baseline IPSC peak amplitude was established over several minutes before
pharmacological additions were performed. AM251 (1117; Tocris Bioscience), a potent CB1
antagonist, was used to study the role of tonic inhibition in CCK+IN/P-cell synapses in the BLA.
AM251 (10 µM) was added to the bath perfusion and IPSCs were continually evoked until no
further changes in peak amplitude were observable. The brain slice was discarded, and equipment

63

was thoroughly cleaned. An additional brain slice was placed into the recording chamber with
fresh aCSF. Baseline IPSC peak amplitude was again established before the addition of 2-AG (20
µM) to the bath perfusion. 2-AG (53847-30-6; Tocris Bioscience) is an endogenous cannabinoid
which we used to study the role of phasic inhibition in CCK+IN/P-cell synapses in the BLA. After
recordings were finished, we determined if there were changes to average IPSC peak amplitude
under control, 2-AG, and AM251 conditions.

Electrophysiology Data Analysis
The effects of CB1 agonism and antagonism on IPSC peak amplitude in CCK+IN/P-cell
synapses in the BLA were studied in two cells from a female CCK-Dlx5/6-ReaChR mouse. As
described in CHAPTER 1, representative IPSC traces, time-course plots, and two-point segment
plots were generated in Origin 6.1. Representative traces were plotted to compare control condition
IPSCs to those under 2-AG and AM251 conditions. Peak amplitudes were used as a quantitative
representation of the amount of GABA release from presynaptic CCK+INs and were calculated by
subtracting baseline sweep current (pre-IPSC) from the maximum positive-going current of the
sweep, which occurred just milliseconds after LED stimulation. Time-course plots were generated
to illustrate the effects of 2-AG and AM251 on peak amplitude. Two-point segment plots were
created to compare average IPSC peak amplitude under control, 2-AG, and AM251 conditions.
Average peak amplitudes for the two pharmacological conditions were determined only after the
point at which IPSCs had stabilized in the time-course plot, approximately ten minutes after
addition to the bath perfusion.
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Results
CB1 Expression in CCK+INs in the BLA and Hippocampus
Confocal images of immunofluorescence in CCK-Dlx5/6-tdT brain slices display
widespread CB1 and CCK expression in the BLA and the HPC (CA3 region) (Figure 14A left/middle). CB1 is labelled with the Alexa 488 (green) fluorophore through secondary/indirect
immunofluorescence while CCK+INs are labelled with tdTomato (red) through dual recombinase
action (see Figure 9A for intersectional strategy). In Figure 14A - left, three CCK+INs are seen
in the midst of several non-labelled cell bodies (black circles) in the BLA. Due to their bulbous
morphology and dense fluorescence, it appears there are an abundance of GABAergic CCK+
terminals in peripheral tissue and around cell bodies. Several thick neuronal processes, likely
primary dendrites, can be seen in the right-hand side of Figure 14A - left. Thinner neuronal
processes, likely the secondary and tertiary dendrites of CCK+INs, are present throughout the
tissue. Also seen throughout the tissue are CB1-contaning neuronal processes, which are especially
prevalent encircling CCK+INs in Figure 14A - left/middle. CB1 expression appears to be present
in thinner projections, likely secondary/tertiary dendrites and terminals. There is no Alexa 488
fluorescence within cell bodies, as CB1 is expressed in the transmembrane domain. There is minor
colocalized signal around the center of the CCK+INs in Figure 14A - left/middle as well as in
what appear to be the processes around non-labelled cell bodies. A cut mask image generated in
Carl Zeiss LSM Software depicts colocalization of tdTomato and Alexa 488 fluorescence Figure
14A - right. Colocalization patterns suggest that synaptic terminals are areas of high combined
CCK/CB1 expression. Some neuronal processes, possibly secondary dendrites, also show
colocalization, albeit at a lower level than synaptic terminals.
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Figure 14B - left/middle depicts fluorescence representing CCK+IN and CB1 expression
in the CA3 region of the HPC in CCK-Dlx5/6-tdT brain slices. Figure 14B - left contains one
CCK+IN with what appears to be high levels of innervation of cells in the stratum pyramidale (SP)
layer. Many cells in the SP are innervated by CCK+IN projections. Additionally, CCK+IN
projections are observable in the transition between the SP and the stratum lucidum (SL), and to a
lesser extent in the larger SL layer. CB1 expression patterns are similar here as in the SP, but with
a greater degree of intensity. In the SP, CB1 appears to be expressed in the synaptic terminals that
comprise perisomatic inhibition patterns (Figure 14B - left). CB1 is also expressed in neuronal
processes which weave in and around cells. Based on morphology, there are many presynaptic
terminals that express CB1. Expression appears to be concentrated on either side of the SP. In the
SL, CB1 expression is weaker, as seen in the right-hand side of Figure 14B - left. Faint Alexa 488
fluorescence is observable in what are probably secondary/tertiary dendrites and synaptic terminals.
Figure 14B - middle depicts a CCK+IN and CB1 expression in the SL layer of CA3. Immediately
visible are the thicker dendritic processes containing CB1 expression. They run throughout the
tissue but are noticeably denser in the top portion of Figure 14B - middle, close to the SP-SL
transition. The cut mask in Figure 14B - right reveals that CCK/CB1 colocalization is mild in the
stratum oriens (SO), moderate in the SL, and strong in the SP. Not every cell in the SP is innervated
by CCK+INs/CB1, as some are indistinguishable from one another like in the lower center portion
of Figure 14B - right.
Pearson’s correlation coefficient (PCC) was used to measure overall colocalization (R) of
CCK and CB1 expression (Figure 14A/B - right). In the BLA, we obtained an R-value of 0.79 and
in the HPC, an R-value of 0.84. We also calculated the Mander’s unweighted colocalization
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coefficient (MCC) for CCK/CB1 signal in these two brain regions. We obtained an MCC of .783
in the BLA and .589 in the HPC.

Figure 14| GABAergic CCK and CB1 expression in the BLA and HPC. Confocal images taken of
immunofluorescence in coronal brain slices from adult CCK-Dlx5/6-tdT mice. CCK+INs and their
projections are tagged with tdTomato (red) while the type-1 cannabinoid receptor (CB1) is tagged with
Alexa 488 (green). Scale is applicable to every images within the figure, as identical settings were used to
capture each image. A| GABAergic CCK and CB1 expression in the basolateral amygdala. Left: CB1 and
GABAergic CCK are expressed in what appear to be synaptic terminals, indicated by small circular areas
of high fluorescence. Fluorescence is also concentrated around cell bodies (black circles) in what appear to
be perisomatic inhibition patterns. Areas of yellow signal contain both Alexa 488 and tdTomato
fluorescence (colocalization). Middle: A CCK+IN is surrounded by what appear to be CB1-containing
terminals. Right: A colocalization cut mask displaying only pixels which contain colocalized GABAergic
CCK and CB1 expression. Non-colocalized pixels are set to zero intensity. B| GABAergic CCK and CB1
expression in the CA3 region of the hippocampus (HPC). GABAergic CCK and CB1-containing processes
innervate many cells and colocalize around cell bodies. Left: In the HPC, what appear to be CB1-containing
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terminals innervate the stratum pyramidale, lucidum, and radiatum layers. Innervation by the CCK+IN
displays similar patterns. Colocalization can be seen in multiple perisomatic inhibition-like circuits. Middle:
A CCK+IN in the stratum radiatum layer of CA3 is appears to be innervated by CB1-containing terminals.
Neuronal processes containing CB1 are seen in the surrounding tissue. Right: A colocalization cut mask
displaying only pixels which contain colocalized GABAergic CCK and CB1 expression in CA3.

CB1 Agonist (2-AG) Reduced IPSC Peak Amplitude in CCK+IN/P-cell Synapses in the BLA
We observed that the CB1 agonist, 2-AG, reduced IPSC peak amplitude in CCK+IN/P-cell
synapses in the BLA of an adult female CCK-Dlx5/6-ReaChR mouse. Addition of 2-AG to the
bath perfusion decreased peak amplitude over a fifteen-minute recording (Figure 15A). A controlcondition trace (black) and a 2-AG-condition trace (forest) are plotted in Figure 15A - left to
represent the differences in peak amplitude. The gradual decrease in IPSC peak amplitude
following addition of 2-AG (20 µM) to the bath perfusion is displayed in a time-course plot
(Figure 15A - middle). 2-AG exerted its full effects eight minutes after addition. The change in
average IPSC peak amplitude before and after 2-AG addition is represented by a two-point
segment plot (Figure 15A - right). The pair of white circles represent the average peak amplitude
before and after 2-AG addition. The average IPSC peak amplitude under control conditions is 225
pA and 167 pA after 2-AG addition (26% decrease).

CB1 Antagonist (AM251) Increased IPSC Peak Amplitude in CCK+IN/P-cell Synapses in the BLA
One P-cell was patched and recorded from the BLA of an adult female CCK-Dlx5/6ReaChR mouse. AM251 applied to the bath perfusion (10 µM) increased IPSC peak amplitude in
a CCK+IN/P-cell synapse in the BLA (Figure 15B). Representative traces depicting changes in
IPSC peak amplitude are plotted in Figure 15B - left. The control trace (black) is 175 pA while
the AM251conditions trace (brown) is 225 pA. The gradual increase in IPSC peak amplitude
following AM251 addition is displayed in a time-course plot (Figure 15B - middle). Stable IPSCs
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were evoked for thirteen minutes before AM251 addition, after which peak amplitude began to
increase, plateauing by minute twenty-three. The average IPSC peak amplitudes under control and
AM251 conditions are represented in a two-point segment plot (Figure 15B - right). The first circle
is the average peak amplitude under control conditions (170 pA), while the second circle is the
average peak amplitude under AM251 conditions (229 pA).

Figure 15| Effects of CB1 modulation in CCK+IN/P-cell synapses in the BLA. Optogenetically-evoked
IPSC were recorded in adult CCK-Dlx5/6-ReaChR brain slices. Scale bars indicate time and current values
for IPSC traces. Drug conditions are indicated in the color-coded timelines. A| Effects of CB1 agonism on
IPSCs in CCK+IN/P-cell synapses. Left: Representative IPSC traces under control (black) and 2-AG (forest
green) conditions. Middle: Time-course plot of IPSC peak amplitude in response to bath addition of 2-AG
(20 µM). 2-AG was added at 2 min and showed full effects by 10 min. Right: Average IPSC peak amplitude
under control and 2-AG conditions. Peak amplitude decreased from 225 pA to 167 pA (-26%). B| Effects
of CB1 antagonism on IPSCs in CCK+IN/P-cell synapses. Left: Representative IPSC traces under control
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(black) and AM251 (brown) conditions. Middle: Time-course plot of IPSC peak amplitude in response to
bath addition of AM251 (10 µM). AM251 was added at 13 min and showed full effects by 23 min. Right:
Average IPSC peak amplitude under control and AM251 conditions. Peak amplitude increased from 170
pA to 229 pA (+34%).

Discussion
Expression of CB1 in CCK+INs in the BLA and HPC
To quantify colocalization, we report both PCC and unweighted MCC values, each of
which has strengths and shortcomings (Dunn, Kamocka, & McDonald, 2011). By obtaining the
unweighted MCC values for tdTomato and Alexa 488 expression in the BLA and HPC, we
acknowledge that the two fluorophores have different intrinsic brightness properties. Unweighted
MCC values are based on pixel population rather than intensity (Adler & Parmryd, 2010), therefore
they provide a better representation of the amount of CCK+IN/CB1 content in tissue. We did not
expect to find unweighted MCC values close or equal to one, as this would indicate every pixel
containing tdTomato fluorescence also contains Alexa 488 fluorescence, represented by total
colocalization (yellow signal) across the entire image. Additionally, a cut mask analysis would
recreate the entire two-channel overlay image, converting red and green signals to yellow based
on the intensity of their colocalization. In both the BLA and HPC we find areas of either no or subthreshold colocalization, represented by black spaces in Figure 14A/B - right. Along similar lines,
we did not expect to find unweighted MCC values approaching zero, indicative of perfectly
opposite tdTomato and Alexa 488 patterns (no colocalization) (Everett, 2016). In addition to MCC
values, we obtained PCC values with the Costes automated method (Costes et al., 2004). PCCs
values are free of the influence of experimenter bias, as fluorescence threshold value cannot be
manually set. If tdTomato and Alexa 488 fluorescence are perfectly linearly related, we would
expect a PCC value of one, and if they perfectly inversely related, we would expect a PPC value
of negative one.
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While direct colocalization analysis has not been performed between CCK+INs and CB1
in brain slices containing the BLA, previous mRNA and protein studies demonstrate a moderatehigh degree (61-88%) of colocalization between CB1 and CCK (Chhatwal et al., 2009; McDonald
& Mascagni, 2001). We obtain a PCC value of 0.79 and an MCC value of 0.783, meaning 62%
(PCC2) and 78% (MCC) of the variability in CB1 (Alexa 488) fluorescence can be explained by
the variability in GABAergic CCK (tdTomato) fluorescence. Despite being done in a novel system,
these colocalization result falls within the range of reported CB1 and CCK colocalization values
for the BLA (Chhatwal et al., 2009; McDonald & Mascagni, 2001).
It has been previously reported that CB1 is present in 82.7% of CCK+ terminals in the CA3
region of the HPC (Foldy, 2006). Furthermore, a majority of CB1 terminals in the SP layer
innervate P-cells while those in SO/SR layers target dendrites (Foldy, 2006). Our cut mask analysis
appears to qualitatively reflect these finding (Figure 14B - right). In the HPC, we obtain a PCC of
0.84 and an MCC value of 0.589, meaning 71% (PCC2) and 59% (MCC) of the variability in CB1
(Alexa 488) fluorescence can be explained by the variability in GABAergic CCK (tdTomato)
fluorescence. I predict this variability to be due to the sensitivity of the MCC to the estimate of
background. A decrease by just one gray level has been associated with a 2% decrease in the overall
estimated overlap of signal in MCC analysis (Dunn et al., 2011). If considering PCC analysis only,
then our R2 value of 71% value is 12% percentage points lower than reported co-expression levels
(Katona et al., 1999). This may be due to variations in technique (i.e. confocal vs electron
microscopy, immunoperoxidase vs immunofluorescence), or suggest that CCK/CB1 colocalization
highly variable.
There are no direct comparisons of CCK/CB1 colocalization between the BLA and HPC
using brain slice immunofluorescence. However, across multiple studies with only minor
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variations in reported expression value, it is clear that GABAergic CCK and CB1 expression are
highly linked in structures like the BLA, HPC, and PFC (Eggan, Melchitzky, Sesack, Fish, &
Lewis, 2010; Katona et al., 1999; Shen, Piser, Seybold, & Thayer, 1996). Between our
colocalization analysis of the BLA and HPC, PCC values are 9% apart while MCC values are 19%
apart. As described above, MCC values are not ideal for our images, but could hold value if we
had lower levels of background Alexa 488 expression. PCC values, while limited in their
application, provide us with non-subjective background determinations. Given that both cut masks
analyses in Figure 14A/B - right were performed using identical detection settings and in the same
brain slice, PCC values present the most controlled measure of overall CCK/CB1 colocalization.

Phasic CB1-mediated Inhibition of GABA Release in CCK+IN/P-cell Synapses in the BLA
We observe a 26% decrease in IPSC peak amplitude (from 224 pA down to 167 pA) when
CCK+IN/P-cell synapses in the BLA were exposed to 2-AG (Figure 15A - right). While our nvalue is not large enough to determine significance, our preliminary finding aligns with what
Rovira-Esteban and colleagues (2017) report. IPSC peak amplitude has been shown to be inhibited
by application of synthetic CB1 agonists in the BLA previously (Katona et al., 2001). Activity of
2-AG, the endogenous CB1 agonist, can be studied by direct application of the agonist, or by
stimulating the synthesis of the agonist in the postsynaptic cell (Yoshida et al., 2011). The latter
method is used by Rovira-Esteban and colleagues (2017) to study transmission from CCK+INs in
the basal amygdala. In order to draw comparisons between their study and ours, the differences in
experimental design must be made apparent.
2-AG is synthesized in postsynaptic cells following depolarization, and retroactively binds
to presynaptic terminals to suppress transmitter release in a system of negative feedback inhibition
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(Zhu, 2005). The mechanism by which 2-AG is synthesized in P-cells and activates CB1 in
presynaptic terminals is known as depolarization-induced suppression of inhibition (DSI), while
the manner in which CB1 then inhibits transmitter release is known as phasic inhibition (Guo &
Ikeda, 2004; Wilson et al., 2001). Rovira-Esteban and colleagues (2017) used DSI to study eCBmediated inactivation of GABA release, whereas we used direct addition of 2-AG to the bath
perfusion to study phasic inhibition in the same cellular circuit. Rovira-Esteban and colleagues
(2017) demonstrate that the actions of 2-AG significantly reduce IPSC peak amplitude to 32% (+/7%) compared to baseline. Our 26% decrease is not as great in magnitude; however it is a
preliminary indicator that eCB-dependent phasic CB1 inhibition of transmitter release in
CCK+IN/P-cell synapses of the BLA is a reproducible finding.

Tonic CB1-mediated Inhibition of GABA Release in CCK+IN/P-cell Synapses in the BLA
We present a recording where IPSC peak amplitude increases by 34% in response to bath
addition of AM251 (Figure 15B - right). As a CB1 antagonist, AM251 blocks phasic, eCBdependent inhibition of CaVs (Lenkey et al., 2015). However, CB1 does not require eCBs to
downregulate CaVs (tonic inhibition). AM251 also blocks tonic CB1 inhibition of CaVs, reducing
the probability of GABA release onto postsynaptic P-cells (Biro, Holderith, & Nusser, 2006;
Delaney, Crane, & Sah, 2007). In addition to blocking tonic CB1-mediated inhibition of CaV2.2
and increasing GABA release probability, it has been proposed that AM251 increases the number
of GABAergic exocytosis cites (Biro et al., 2006; Delaney et al., 2007; Rovira-Esteban et al., 2017).
This would allow for a greater amount of GABA release from CCK+INs, represented by stronger
chloride flow and subsequently greater IPSC peak amplitude in postsynaptic P-cells.
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Similar to our observation of 34% increase, Rovira-Esteban and colleagues (2017) report
a 45% increase in IPSC amplitude upon AM251 addition in CCK+IN/P-cell synapses in the BLA.
The 11% discrepancy despite being from the same circuits can be potentially explained in several
ways. Rovira-Esteban and colleagues (2017) have an n-value of 10, whereas we obtained an nvalue of 1 before their paper was released. Additionally, a 34% increase falls within their reported
standard deviations. We controlled for variables that could have given us false confirmation of
their observations. For example, with too high a concentration of AM251, we may have observed
a stronger increase in IPSC peak amplitude. The peak amplitude increase we observed with 10 µM
proved to be lower, but within deviation range, of the increase Rovira-Esteban and colleagues
(2017) observed using a 5 µM dose. Overall, our mouse line and initial experiments serve as a tool
for further studies on the molecular components underlying CB1-mediated inhibition in the BLA.

Additional Considerations for Future Research
Our future interests center on describing the regulatory role CB1 exhibits on CaV2.2
channels in specific cell populations in the BLA (see NIH: R00-MH099405). Ideally, we aim to
prove that CB1 inhibits CaV2.2 channels to control transmission in CCK+IN/P-cell synapses. If
present, CB1-mediated inhibition of CaV2.2 would demonstrate tonic inhibition in the BLA, as it
occurs independent of eCBs. To accomplish this, we would perform electrophysiology recordings
from P-cells and quantify the component of IPSCs that is sensitive to ω-Conotoxin GVIA under
the presence of AM 251. Additionally, we aim to show that eCBs acting through CB1 are powerful
anxiolytics via their inhibition of CaV2.2 channels in amygdala synapses. eCB-mediated
modulation of CaV2.2 would be considered phasic inhibition, as it is ligand-dependent and short-
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term, dissipating after eCBs have been cleared from the presynaptic terminal. This system can be
studied through DSI experimentation as described by Ramikie and Patel (2012).
Additionally, we propose to study if CB1-mediated inhibition of CaV2.2-dependent
GABAergic release in the BLA is elevated during anxiety states. Behavioral studies like repetitive
stress models, intended to induce anxiety-like behavior, have shown long-lasting changes to the
eCB system in several brain areas including the BLA (M. N. Hill et al., 2010; Hill et al., 2009;
Lafenêtre, Chaouloff, & Marsicano, 2007; Patel et al., 2009; Patel, Roelke, Rademacher, & Hillard,
2005; Qin et al., 2015; Viveros, Marco, & File, 2005). Additionally, anxiety is linked to reduced
GABAergic transmission in the BLA (Ehrlich et al., 2009). Postsynaptic modulations have been
observed during anxiety, but little has been shown regarding the impact of anxiogenic stimuli on
effectors of CB1, like CaV2.2 channels. It may be the case that that anxiety states cause enhanced
CB1 inhibition of CaV2.2 channels in CCK+INs. To determine this, we will put mice through an
established anxiety-inducing behavioral paradigm and measure IPSCs in CCK+IN/P-cells
synapses to assess the levels of phasic and tonic inhibition between anxious and non-anxious
animal models.
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CHAPTER 3: ASSESSING REGULATION OF GABA RELEASE AND INTRINSIC
FIRING BY CAV2.2 IN THE INFRALIMBIC CORTEX
Abstract
The medial prefrontal cortex (mPFC) is an area of the brain involved in emotional
processing. Rodent studies have demonstrated that neuronal output from the mPFC is crucial for
the expression and conditioning of fear. Disruptions in the activity of the mPFC are associated
with deficits in fear extinction, a process which is also disrupted by anxiety disorders like posttraumatic stress. Chronic and traumatic stress have been shown to negatively impact the mPFC at
the cellular level; pyramidal cells (P-cells), the primary excitatory projections in the mPFC,
become unstable and less responsive. In turn, the brain regions which are innervated by these Pcells are adversely affected. The resultant behavioral consequences vary depending upon the
connection type. A sub-region of the mPFC known as the infralimbic cortex (IL) is involved in
extinction memory. The IL is organized into multiple layers in which P-cells establish connections
with the basolateral amygdala (BLA). The BLA is crucial for normal fear-related learning,
particularly fear acquisition and fear extinction. Irregular activity in the connections between the
IL and the BLA promote insufficient fear regulation and responses, however the underlying
cellular physiology is not well understood. To help better understand the neurobiology of fear
processing and anxiety disorders, we targeted the N-type calcium channel (CaV2.2) in this study.
In limbic structures like the hippocampus, these channels have been shown to be expressed in the
presynaptic terminal of cholecystokinin-positive interneurons (CCK+INs) and in P-cells, coupled
to calcium-activated potassium channels. However, no data has been presented describing if these
CaV2.2 roles are conserved within the IL. A series of electrophysiology and confocal microscopy
experiments were conducted to study presynaptic and somatic CaV2.2 in the IL. We determined
that inhibitory postsynaptic currents (IPSCs) in GABAergic/P-cell synapses are significantly
reduced (46%) following CaV2.2 blockade (p = .00015). We found that CaV2.2 blockade had no
significant effect on the firing properties of P-cells (p = .204). Confocal images depicted densely
innervated P-cells in layers 2, 3, and 5. Electrophysiological studies revealed that the peak
amplitude of IPSCs in CCK+IN/P-cell synapses is not significantly affected by CaV2.2 blockade
(p = .122). We conclude that neurotransmitter release is partially CaV2.2-dependent in
GABAergic/P-cell synapses and not significantly CaV2.2-dependent in CCK+IN/P-cell synapses
in the IL, suggesting other voltage-gated calcium channel subtypes (CaVs) are involved. Our
findings serve as a foundation for further research into the cellular mechanisms underlying anxietyrelated circuits in the IL.
Introduction
The medial prefrontal cortex (mPFC) is involved in the processing and behavioral
responses to fear and anxiety. Of the multiple sub-regions that comprise the mPFC, two areas in
particular are of interest to researchers for their differentiable effects on anxiety-like behavior
(Sierra-Mercado et al., 2011). The prelimbic region of the mPFC (PL) facilitates behavioral
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responses to fearful stimuli (fear expression) through its interconnections with the basolateral
amygdala (BLA) (Sullivan & Gratton, 2002). Ventral to the PL, the infralimbic region of the mPFC
(IL) is involved in extinction of conditioned fear, a product of extinction-related neuronal plasticity
in the hippocampus (HPC) and BLA (Do-Monte et al., 2015). Dysfunction in mPFC-amygdala
pathways are observable in patients with anxiety disorders. Deficient recruitment of the mPFC is
observed during the process of fear inhibition in patients with generalized anxiety disorder (GAD)
(Greenberg et al., 2013). Patients with post-traumatic stress disorder (PTSD) exhibit decreased
mPFC activation and increased amygdala activation in response to trauma-related cues (Shin et al.,
2004). Additionally, reduced mPFC activity in PTSD has been associated with impaired fear
extinction recall (Bremner et al., 2005) and greater symptom severity (Shin et al., 2005). In animal
models, mPFC function has been associated with the expression of anxiety-like behaviors and the
extinction of conditioned fear, both of which can be impaired with selective inactivation of the
mPFC (Sierra-Mercado et al., 2006, 2011). Neuronal models of anxiety disorders have led to the
belief that reduced mPFC function, in combination with over-excitation in the amygdala, mediate
the dysregulation of fear responses (Rauch, Shin, & Wright, 2006). While the anxiety-related
behavioral components of these connections have been extensively studied, their underlying
neurobiology is less understood.
The process of fear extinction is of great concern for treating anxiety disorders like PTSD
(Johansen et al., 2011; Shin et al., 2004) as sufferers are unable to extinguish anxiety-inducing
memories developed in response to previous trauma. Accordingly, understanding the molecular
mechanisms underlying IL-BLA connections may provide insight as how anxiety-related neuronal
output is regulated (Johansen et al., 2011). In mice, the IL is divided into multiple layers (L1, L2/3,
L5, and L6) based on cell types, projections, and local circuit organization (Allene, Lourenço, &
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Bacci, 2015; Allen Mouse Brain Atlas). Across layers, a majority of neurons are excitatory P-cells
(approximately 80%), while a minority are inhibitory interneurons (INs), including basket cells
(BCs), dendritic cells, and axo-axonic cells (Allene et al., 2015; Riga et al., 2014). P-cells can be
found in L2/3, L5, and L6 while INs are found within every layer (Cruikshank et al., 2012; Ma,
Yao, Fu, & Yu, 2014; Riga et al., 2014). The projections from P-cells in L5/L6 are deep, generally
targeting subcortical areas, while the projections from L2/3 are more superficial, generally
targeting other cortical areas (Douglas & Martin, 2004). The intrinsic properties and circuit
organization of these cells is of interest, as regulating their interactivity is required for normal fear
and anxiety-related processing (Sierra-Mercado et al., 2006). P-cells in L2/3 and L5 are known to
make reciprocal connections with the BLA (Allene et al., 2015; Ferreira et al., 2015). IL-BLA
connections receive various excitatory inputs, primarily from the contralateral mPFC, midline
thalamic nucleus, BLA, and ventral HPC (Riga et al., 2014). Additionally, IL-BLA connections
receive various inhibitory inputs, which present themselves as targets for potentially mediating
fear extinction at the level of the IL (Do-Monte et al., 2015).
Two major forms of inhibition are exerted upon IL-BLA projections (Allene et al., 2015).
Dendritic inhibition of P-cells is facilitated by Martinotti cells and neurogliaform cells, two IN
subtypes located in L2/3-L6 and L1, respectively (Palmer, Murayama, & Larkum, 2012; Y. Wang
et al., 2004). Perisomatic inhibition is facilitated by parvalbumin-containing (PV+) and
cholecystokinin-containing (CCK+) basket cells (BCs), two additional IN subtypes which synapse
onto the soma of local P-cells (Freund, 2003; Freund & Katona, 2007). Dendritic inhibition can be
evoked in a feed-forward manner by afferent projections. For example, thalamic input has been
shown to excite dendritic INs in L1, which then inhibit P-cells in L2/3 (Cruikshank et al., 2012).
Perisomatic inhibition is a form of feedback inhibition, where the firing of P-cells stimulates local
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BCs to then regulate P-cell activity. Whereas the role of PV+BCs in perisomatic inhibition has
been studied in L2/3, L5, and L6 (layers containing IL-BLA projections), the role of CCK+BCs in
the same circuits has not (Allene et al., 2015; Armstrong & Soltesz, 2012; Freund, 2003).
Research suggests that in cortical regions, voltage-gated calcium channels (CaVs) are
involved in regulating GABA release from INs and the intrinsic firing properties of P-cells
(Ferreira et al., 2015; Freund, 2003; Jasnow et al., 2009; Kurihara & Tanabe, 2003; Loane et al.,
2007). However, the role of CaVs in specifically the IL has not been functionally investigated,
representing an important target by which anxiety may be regulated. Of the multiple CaV subtypes,
N-type CaVs (CaV2.2) are distinguished for their anxiety correlation (Lotarski et al., 2011). GABA
release from presynaptic INs was shown to be entirely dependent on CaV2.2 in the HPC (Szabo et
al., 2014), but it is not known if this is conserved in the IL. Additionally in the HPC, CaV2.2 was
shown to modulate the intrinsic firing of P-cells through coupling to calcium-activated potassium
channels (Loane et al., 2007). CaV2.2 is also involved in the intrinsic firing of P-cells in the deep
cerebellar nuclei, selectively regulating their spontaneous activity (Alviña & Khodakhah, 2008).
As is the case for the presynaptic region, it has not been determined if these intrinsic roles of
CaV2.2 are conserved in the IL.
The CaVs associated with GABA release from the multiple IN subtypes found in the IL
have not been fully detailed. PV+BCs, Martinotti cells, and neurogliaform cells have been shown
to express P/Q-type CaVs (Bartos & Elgueta, 2012), L-type CaVs (Wang et al., 2004), and further
L-type CaVs (Li, Stewart, Canepari, & Capogna, 2014), respectively. On the other hand, the
expression of CaV2.2 has been found in CCK+INs in the BLA, HPC, and mPFC (Ali, 2011; Eggan
et al., 2010; Freund, 2003; Jasnow et al., 2009). GABA release from CCK+INs in the HPC was
determined to be entirely-dependent on CaV2.2 (Szabo et al., 2014). This does not imply that

79

CCK+INs in the IL will function in the same manner however, as there are known variations in
CCK+IN properties across brain regions, potentially due to ion channel variations (Kullmann,
2011). GABA release from two additional IN subtypes, chandelier and bipolar cells, has not been
associated with any CaV subtype(s). In the IL, chandelier cells form inhibitory connections on the
axon-initial segment of P-cells, while bipolar cells are thought to inhibit other INs (Allene et al.,
2015). Little is known about the synaptic properties of these INs, and their CaV-dependency has
yet to be determined for the IL.
Ultimately, there is a lack of direct functional studies on the role of CaV2.2 in the
infralimbic cortex. Our goal is to determine this role, specifically in 1) GABA release from the
general population of INs onto P-cells in L2/3, 2) GABA release from local CCK+INs onto P-cells
in L2/3, and 3) the firing pattern and spike frequency of P-cells in L2/3. We hope this work will
contribute to the overall understanding of the molecular mechanisms underlying P-cell regulation
in the IL, regulation which is crucial for normal fear extinction processes and is disrupted in
anxiety disorders.

Methods
Animal Models
Refer to CHAPTER 1 for more detailed information on the breeding, background, and
research applications of our CCK-Dlx5/6-tdT and CCK-Dlx5/6-ReaChR mouse models. CCKDlx5/6-tdT mice were used in fluorescence experiments to visualize CCK+INs in the IL and greater
mPFC. CCK-Dlx5/6-ReaChR mice were used in electrophysiology experiments to study the role
of CaV2.2 in CCK+IN/P-cell synapses in the IL. Wild-type mice were used in electrophysiology
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experiments to study the role of CaV2.2 in GABAergic IN/P-cell connections as well as P-cell
intrinsic firing properties.

In Vitro Brain Slice Preparation and Electrophysiology
Refer to CHAPTER 1 for more detailed information on the preparation of live brain slices
for electrophysiology experiments as well as a description of our electrophysiology rig. Protocols
and equipment were conserved in this experiment with minor modifications. Slices containing the
mPFC (rather than the BLA) were prepared from adult wild-type in addition to CCK-Dlx5/6ReaChR mice.

Electrophysiology - Electrical Stimulation and Recording of GABAergic IN/P-cell Connections
To study the role of CaV2.2 in neurotransmitter release from GABAergic INs onto P-cells
in the IL, we determined the sensitivity of electrically-evoked IPSCs to CaV2.2-blockade via
addition of ω-Conotoxin GVIA (CTX) (ab120215; Abcam) to the bath perfusion. To stimulate
neurotransmitter release from GABAergic INs, we used a concentric bipolar electrode
(CBBPF100; FH-Co), which was connected to a stimulus isolator (A365; WPI) and mounted to a
three-axis dovetail manipulator (MX130L, Siskiyou Co) attached to our microscope stage. Coronal
brain slices containing the mPFC were prepared from adult wild-type mice and mounted in the
recording chamber. Figure 16 - top left demonstrates our recording approach. The concentric
bipolar electrode was placed in the Pia/L1 of the IL (Figure 16 - top left, yellow circle) where INs
are exclusively GABAergic (Cruikshank et al., 2012). A micropipette was used to perform wholecell patch-clamps on P-cells in layer 2/3 (Figure 16 - top left, red circle). Magnifying the patch,
P-cells were distinguishable from other cell types by their piriform morphology and medial axonal
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projections (Figure 16 - top middle, red circle). P-cells were held at 0 mV and an electricallyevoked IPSC protocol was applied though pCLAMP 10 software. 1000 ms sweeps began every 15
seconds in which a .1 ms electrical stimulation was delivered to the brain slice via the concentric
bipolar electrode. The stimulus isolator was used to adjust the amperage delivered by the electrode
as a percentage of 1 mA, allowing us to alter the initial peak amplitude of the IPSCs. Initial peak
amplitude was set to between 200-700 pA in order to be large enough for pharmacological changes
to be observed while remaining small enough as to not exhaust neurotransmitter release or harm
the brain slice.
Once satisfactory IPSCs were evoked, pharmacological recordings began. CPP (20 µM)
and DNQX (10 µM), NDMA and AMPA/Kainate antagonists, respectively, were added to the bath
perfusion to ensure we only recorded the GABAergic components of electrically-evoked
neurotransmitter release. The initial few minutes of each recording was used to establish a baseline
peak amplitude for control conditions, prior to the addition of pharmacological agents. CTX (400
nM) was added to the bath perfusion to observe if there were any significant effects of CaV2.2
blockade on peak amplitude. IPSCs were continually evoked until no further changes in peak
amplitude were observable, i.e. a ‘plateau’ phase. CTX-dependent effects typically took fifteentwenty minutes to fully present. Next, bicuculline (BIC) (ab120107; Abcam), a GABAA antagonist,
was added to the bath perfusion (100 µM) to eliminate IPSCs and confirm the bath perfusion was
delivering pharmacological agents to the brain slice. Recordings (n = 6 cells) were typically
between 45-60 minutes in length. Once a recording was finished, brain slices were discarded and
aCSF was replaced. Electrophysiology equipment was washed thoroughly with hydrogen peroxide
and MilliQ water to avoid pre-exposing subsequent brain slices to pharmacological agents.
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Representative traces were plotted in Origin 6.1 to compare IPSCs evoked under control,
CTX, and BIC conditions. Peak amplitudes, used as a quantitative representation of the amount of
neurotransmitter release from GABAergic INs, were calculated by subtracting baseline sweep
current (pre-IPSC) from the maximum positive-going current of the sweep which occurred just
milliseconds after LED stimulation. A time-course plot was created to represent the changes in
IPSC peak amplitude (pA) in response to pharmacological conditions over the duration of the
recording (min). A two-point segment plot was created to compare average IPSC peak amplitude
under control and CTX conditions across the six cellular recordings. Average peak amplitudes
were determined after the point at which IPSC peak amplitude remained relatively stable in the
time-course plot. A one-tailed paired t-Test was run comparing the average peak amplitude under
control and CTX conditions across the six cellular recordings. The mean, standard deviation (SD),
and standard error of the mean (SEM) for the average peak amplitude under control and CTX
conditions across all recordings were calculated. This mean (gray circles) and SEM (vertical black
lines) were added to the two-point segment plot.

Fluorescence Stainings & Confocal Microscopy
Refer to CHAPTER 1 for more detailed information on fluorescence and confocal imaging
in CCK-Dlx5/6-tdT mice. Protocols and equipment were conserved in this experiment, except were
done to section, stain, and image brain slices containing the mPFC rather than the BLA.

Electrophysiology - Optogenetic Stimulation of IPSCs in CCK+IN/P-cell Synapses
To determine the role of CaV2.2 in CCK+IN/P-cell synapses in the IL, we determined the
sensitivity of IPSCs to CaV2.2 block via CTX. Whole-cell patch-clamp recordings were performed
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on P-cells in the IL of adult CCK-Dlx5/6-ReaChR mice (n = 8). P-cells were held at 0 mV and
IPSCs were evoked using optogenetic simulation. Recording protocols were programmed in
pCLAMP 10 software. 1000 ms sweeps containing a 0.1 ms stimulation began every twenty
seconds. ‘Control’ IPSCs were evoked for several minutes to establish a baseline peak amplitude.
CTX (300 nM) was then added to bath perfusion. IPSCs were continually evoked until no further
CTX-dependent change to peak amplitude were observable. BIC (100 µM) was then added to the
bath perfusion and IPSCs were evoked until eliminated. After recordings were finished, brain
slices were discarded and aCSF was replaced. Equipment was washed thoroughly before a
subsequent slice was added to the chamber for further recordings Data analysis was performed in
an identical manner as described above for electrically-evoked IPSCs.

Electrophysiology - Modulation of P-Cell Intrinsic Firing Properties by Cav2.2
To study the role of CaV2.2 in P-cell intrinsic firing properties in the IL, we determined the
sensitivity of action potential spike train firing pattern and spike frequency to CTX and cadmium
chloride (CdCl2). CdCl2 is a reversible CaV antagonist which allowed us to observe if CaV subtypes
other than CaV2.2 modulated P-cell intrinsic firing properties. Whole-cell patches were performed
on P-cells in L2/3 of the IL in wild-type mice. A current-clamp was applied, and a ramp protocol
was run to determine the activation threshold for each P-cell. The amount of current injected to
evoke action potential spike trains was then set to +10 pA larger than this threshold and ranged
from 50-120 pA across recordings. Initial firing patterns were compared to previous research
(Faber et al., 2001; Rainnie et al., 1993; Zaitsev et al., 2012) to confirm we recording from P-cells
and not INs. Three second square-pulse currents injections were applied every 45 seconds to
produce action potential spike trains at an interval that was both conducive to cell health and
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allowed for pharmacologically-induced changes to be observed. Control firing patterns and spike
frequencies were determined over a 5-10 min period before pharmacological additions began.
Using a valve controller (VC-6; Warner Instruments), three perfusion baths were applied in
sequential order. Bath #1, the control condition bath, contained regular aCSF. Bath #2, the CTX
condition bath, contained aCSF + 300 nM CTX. Bath #3, the CdCl2 condition bath, contained
aCSF + 100 µM CdCl2. Given the slow diffusion time of CTX, bath #2 was applied for at least 20
minutes before switching to bath #3. After CdCl2-dependent effects plateaued, we applied bath #1
for a second time to ‘wash’ the brain slice. Washes removed CdCl2 from the perfusion and were
used to determine if the effects we observed were due to CaV block and not damage to the cell.
Once recordings were complete, brain slices were discarded, and equipment was washed
thoroughly with hydrogen peroxide and MilliQ water to avoid pre-exposing subsequent slices to
pharmacological agents.
Representative firing patterns from the control, CTX, and CdCl2 conditions were plotted
in Origin 6.1. Spike frequency was calculated by diving the number of spikes in an action potential
spike train by the duration of the current injection (three seconds). The event detection function in
Clampex 10.6 was used to count the number of action potential spikes (or ‘events’) in each sweep.
Spike frequencies were charted alongside the time at which the corresponding sweep began (i.e.
sweep one = 0 min, sweep two = 0.75 min, sweep three = 1.5 min, etc.). Time-course and twopoint segment plots were created in Origin 6.1 to demonstrate represent the effects of
pharmacological agents on spike frequency in a single recording and across all cellular recordings,
respectively. A one-tailed paired t-Test was run comparing the average spike frequency under
control and CTX conditions across six cellular recordings. The mean, SD, and SEM for the average
spike frequency amplitude under control and CTX conditions across recordings were calculated.

85

This mean (gray circles) and SEM (vertical black lines) were added to the two-point segment plot.
Additionally, a one-tailed paired t-Test was performed, and the mean, SD, and SEM were
calculated for the average spike frequency under control and CdCl2 conditions in a total of four
cellular recordings. This data is not represented in any figure.

Results
CaV2.2 Blockade Reduced IPSC Peak Amplitude in GABAergic IN/P-cell Synapses in the IL
Using the recording approach depicted in Figure 16 - top left/top middle, we found that
IPSC peak amplitude in GABAergic IN/P-cell synapses decreases when CaV2.2 is blocked.
Electrophysiology recordings were performed in six cells from two male and two female wild-type
mice. Individual traces comparing IPSC peak amplitude under control, CTX, and BIC conditions
were plotted in Figure 16 - top right. The control peak amplitude (black) is 743 pA, the CTX peak
amplitude (red) is 523 pA, and the BIC peak amplitude (navy) is 28 pA. CaV2.2 blockade was slow
to take effect; peak amplitude decreased over a thirty-or-so minute window before steadying
(Figure 16 - bottom left). BIC effects were much quicker, completely eliminating IPSCs in about
five minutes. Peak amplitude decreased in response to CTX across all recordings (Figure 16 bottom right). Percentage decrease of peak amplitude from control to CTX conditions ranged from
24% to 70%, averaging to 46% (SD = 20%, SEM = 8%). A one-tailed paired t-Test from the twopoint segment plot gives a p-value of 0.00015, meaning the CaV2.2-mediated decrease in peak
amplitude is statistically significant. The average control peak amplitude was 331.4 pA (SD = 175
pA, SEM = 71 pA) while the average CTX condition peak amplitude was 202 pA (SD = 161 pA,
SEM = 66 pA).
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Figure 16| Effects of CaV2.2 antagonism on IPSCs in GABAergic IN/P-cell synapses in the IL. IPSC
recordings were performed in the IL of adult wild-type mice. Scale bars represent tissue width in DIC
images and time/current values in IPSC traces. Pharmacological conditions are indicated in the color-coded
timeline. Top left: Electrophysiology setup for IL recordings. A concentric bipolar microelectrode (yellow
circle) is placed in the Pia/L1 to stimulate GABA release from INs while P-cells in L2/3 are patched with
a micropipette (red circle). Top middle: Magnification of the micropipette patch of a L2/3 P-cell (red circle).
Axons of surrounding P-cells are directed towards the medial portion of the brain slice, represented by thin
projections at the apex of the soma. Top right: Representative traces from IPSCs in control, w-Conotoxin
GVIA (CTX), and bicuculline (BIC) conditions. Throughout all recordings, the NMDA and AMPA/Kainate
antagonists CPP and DNQX were present in the bath perfusion. The control (black) peak amplitude = 398
pA, the CTX (red) peak amplitude = 222 pA, and the BIC (blue) peak amplitude is < 10 pA. Bottom left:
Time-course plot of IPSC peak amplitude before and after bath addition of CTX (400 nM) and BIC (100
µM). Peak amplitude begins at 400 pA but drops to under 200 pA following CTX addition. Bottom right:
Two-point segment plot of average IPSC peak amplitude under control and CTX conditions. Each pair of
circles represents one cellular recording (n = 6). CTX addition significantly decreases IPSC peak amplitude
(p = 0.00015, one-tailed paired t-Test). The mean decrease was 46% (SD = 20%, SEM = 8%). Grey circles
represent the mean IPSC peak amplitude under control (331 pA) and CTX (202 pA) conditions. Vertical
black lines represent the SEM of each mean (71 pA and 66 pA, respectively).
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Expression of CCK+INs in the IL
We present confocal images of fluorescence staining in the mPFC of an adult CCK-Dlx5/6tdT mouse. The slice contains mostly IL, though the bottom portion contains part of the dorsal
peduncle and taenia tecta (Allen Mouse Brain Atlas). CCK+INs and their extensive innervation
are observable in what morphologically appear to be L2/3 and L5 of the IL (Figure 18). tdTomato
(red) fluorescence labels GABAergic CCK+INs and their neuronal processes while SYTO-13
(green) fluorescence labels all cell bodies. CCK+INs are sparse in the medial region of each
hemisphere (likely L1) and the anterior forceps of the corpus callosum (Figure 18 - left). Neuronal
processes of CCK+INs are more apparent in the lateral aspects of the IL, with the highest
expression located in what is likely L5. The dorsal peduncle and taenia tecta, considered by some
as part of the ventral IL (Swanson, 2004), appear to express a considerable number of CCK+INs
and processes. There are many non-labelled cells around which patterns characteristic of
perisomatic inhibitory are observable (Figure 17 - left). SYTO-13 fluorescence indicates that
medial regions of the IL (L1 and the pia) are sparse of cell bodies (Figure 17 - middle). There is a
clustering of cell bodies in the divide between the two hemispheres, particularly where blood
vessels are typically found. Cell bodies appear to be more tightly packed in the most medial portion
of L2/3 but more evenly distributed in the outermost aspects of the left-hand hemisphere in Figure
17 - middle. An overlay of tdTomato and SYTO-13 signal is located in Figure 17 - left.
Colocalization (yellow) occurs in all GABAergic CCK+INs, which are not uniformly distributed
throughout the slice.
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Figure 17| GABAergic CCK Expression in the IL. Fluorescence images of a coronal brain slice
containing the IL from an adult CCK-Dlx5/6-tdT mice. CCK+INs and their projections are tagged with
tdTomato (red) while cell bodies are stained with SYTO-13 (green). Scale bars indicate tissue width and
apply to all images within the figure. Left: Expression of GABAergic CCK+INs is prevalent in L2/3 and
L5 of the IL. Superficial layers (L1, pia matter) have lower expression. Web-like patterns of GABAergic
CCK+IN processes can be seen in L2/3 and L5. Middle: Cell bodies are sparse and disorganized in L1 and
the pia matter. However, the deeper layers of the IL show more organized cellular patterns. Right: A twochannel overlay of SYTO-13 and tdTomato signals shows colocalization (yellow) in the cell bodies of
GABAergic CCK+INs.

CaV2.2 Blockade did not Significantly Alter IPSC Peak Amplitude in CCK+IN/P-cell Synapses
In Figure 18 we present data illustrating there is no statistically significant change in IPSC
peak amplitude following CaV2.2 block in CCK+IN/P-cell synapses of the IL. The effects of CTX
and BIC on peak amplitude were studied in eight cells from three male and three female adult
CCK-Dlx5/6-ReaChR mice. Representative traces of IPSCs from control, CTX, and BIC
conditions were plotted in Figure 18 - top right. The control peak amplitude (black) was 177 pA,
the CTX peak amplitude (red) was 202 pA, and the BIC peak amplitude (navy) was 5 pA. Over a
thirty-minute window, no statistically significant change in average peak amplitude was detectable
(Figure 18 - left). Within ten minutes of addition to the bath perfusion, BIC eliminated IPSCs.
Each pair of circles in the two-point segment plot represents the average peak amplitude under

89

control and CTX conditions for a single cellular recording (n = 8) (Figure 18 - bottom right).
Average peak amplitude decreased in four cells and slightly increased in another four. Decreases
ranged from 6-49% and increases from 7-23% with a mean change of -9% (SD = 26%, SEM =
9%). The average IPSC peak amplitude was 386 pA (SD = 282 pA, SEM = 100 pA) for control
conditions, and 297 pA (SD = 131 pA, SE = 46 pA) for CTX conditions. A one-tailed paired t-Test
from this plot gives a p-value of 0.122, meaning there is no statistical significance to the changes
in average peak amplitude when CaV2.2 was blocked.

Figure 18| Effects of CaV2.2 antagonism on IPSCs in CCK+IN/P-cell synapses in the IL.
Optogenetically-evoked IPSCs were recorded from L2/3 P-cells in the IL of adult CCK-Dlx5/6-ReaChR
mice. Left: Time-course plot of IPSC peak amplitude under control, w-Conotoxin GVIA (CTX), and
bicuculline (BIC) conditions, indicated in the color-coded timeline. Average peak amplitude was not
significantly altered by CTX (300 nM) addition to the bath perfusion. IPSCs were eliminated by BIC (100
µM). Top right: IPSC traces representing peak amplitude under each pharmacological condition. Peak
amplitude under control (black) conditions = 180 pA, CTX (red) conditions = 200 pA, and BIC (blue)
conditions = 0 pA. Scale bars represent time and current values for IPSC traces. Bottom right: Two-point
segment plot of average IPSC peak amplitude under control and CTX conditions. Each pair of circles
represents one cellular recording (n = 8). The mean change was -9% (SD = 26%, SEM = 9%). Grey circles
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represent the mean IPSC peak amplitude under control (386 pA) and CTX (297 pA) conditions. Vertical
black lines represent the SEM (100 pA and 47 pA, respectively). CTX addition to the bath perfusion did
not statistically significantly change IPSC peak amplitude (p = 0.122, one-tailed paired t-Test).

CaV2.2 Blockade did not Significantly Alter P-cell Intrinsic Firing Properties in the IL
We present data demonstrating that CaV2.2 does not play a statistically significant role in
the action potential spike train firing patterns, nor the spike frequency of P-cells L2/3 of the IL. A
total of six P-cells were recorded from in this experiment, four cells from two male and two cells
from two female wild-type mice. Firing patterns of action potential spiking under control, CTX,
and CdCl2 conditions are located in the top-half of Figure 19. A non-adapting initial bursting
pattern at 3.33 Hz was evoked under control conditions, a non-adapting initial bursting pattern at
4 Hz was evoked under CTX conditions, and an adapting bursting pattern at 9 Hz was evoked
under CdCl2 conditions. Spike frequencies remained between 3.33 Hz and 4.33 Hz under control
and CTX conditions but increased to between 7.67 Hz and 9 Hz under CdCl2 conditions (Figure
19 - bottom left). Each pair of circles in the two-point segment plot represents the change in firing
frequency after CTX addition for a given cell (n = 6) (Figure 19 - bottom right). From control to
CTX conditions, average spike frequency decreased slightly in three cells and increased slightly
in the remaining three. Decreases ranged from 3-6% and increases from 20-39% with a mean
change of +13% (SD = 18%, SEM = 7%). A two-tailed paired t-Test from this plot gives a p-value
of 0.204, indicating there is no statistically significant change in P-cell spike frequency when
CaV2.2 is blocked. CdCl2 was applied to four recordings (not shown). Increases in spike frequency
from control to CdCl2 conditions ranged from 32-180% with a mean increase of 110% (SD = 62%,
SEM = 31%). The average P-cell spike frequency was 4.53 Hz (SD = 1.21 Hz, SEM = .49 Hz)
under control conditions, 5.03 Hz (SD = 1.08 Hz, SEM = .44 Hz) under CTX conditions, and 9.77
Hz (SD = 2.82 Hz, SEM = 1.41 Hz) under CdCl2 conditions.
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Figure 19| Effects of CaV2.2 antagonism on P-cell intrinsic firing pattern and spike frequency in the
IL. Square-pulse currents were injected into P-cells and action potential spike trains were recorded in the
IL of adult wild-type mice. Scale bars represents current and time values for the three firing patterns. Top
left: Spike train evoked under control conditions. P-cell displayed a non-adapting firing pattern with initial
bursting (3.33 Hz). Top middle: Spike train evoked under CTX conditions. P-cell continued to display a
non-adapting firing pattern with initial bursting, but two additional spikes occurred (4 Hz). Top right: Spike
train evoked under CdCl2 conditions. P-cell displayed a bursting firing pattern with adaptation. Activation
threshold became more positive and the number of spikes increased dramatically (9 Hz). Bottom left: Timecourse plot of P-cell spike frequency before and after addition of CTX (300nM) and CdCl2 (100 mM) to
the bath perfusion. Pharmacological conditions are indicated in the color-coded timeline. Spike frequency
did not significantly change from control to CTX (300nM) conditions, but dramatically increased under
CdCl2 (100 µM) conditions. Wash with clean aCSF partially reduced increases to spike frequency caused
by CdCl2. Bottom right: Two-point segment plot of average spike frequency under control and CTX
conditions. Each pair of circles represents one cellular recording (n = 6). CTX addition does not statistically
significantly affect average spike frequency (p = 0.204, two-tailed paired t-Test). Mean spike frequency
increase was +13% (SD = 18%, SEM = 7%) from control to CTX conditions. Grey circles represent the
mean spike frequency under control (4.53 Hz) and CTX (5.03 Hz) conditions. Vertical black lines represent
the SEM for each mean (.49 Hz and .44 Hz, respectively).
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Discussion
GABA Release from GABAergic IN/P-cell Synapses is Partially CaV2.2-dependent in the IL
The reduction of peak amplitude in our IPSC recordings in the presence of CTX indicate
that CaV2.2 regulates neurotransmitter release from GABAergic INs onto P-cells in L2/3 of the IL.
The validity of this claim is supported by our procedural controls and additional observations. By
performing all recordings in the presence of glutamatergic antagonists (CPP and DNQX), we
ensured IPSCs contained only GABAergic components, which we additionally validated with BIC.
Additionally, we validated that sufficient CTX concentration had been applied during each
recording, increasing concentration by 100 nM doses incrementally up to 400 nM, even after the
decreased in IPSC amplitude had plateaued. If CaV2.2 were either not present or had no functional
role in GABA release, we would observe no significant changes in peak amplitude from control to
CTX conditions. While peak amplitude decreases are reproducible, they are not uniform. There is
likely variation in CaV2.2 expression in the presynaptic INs located in and around L1, as CTX
conditions result in a range of decreases, from 24% to 70%. The larger decreases may represent Pcells that are innervated by more heavily CaV2.2-dependent INs, whereas the lower decreases
represent less CaV2.2-dependent innervation. In either case, additional CaV subtypes are likely
involved. To determine the identity of these other CaVs, further specific CaV antagonists like SNX482 (CaV2.3) and ω-Agatoxin IVA (CaV2.1) could be applied during future recordings.
CaV2.2-dependent GABA release is likely observable in multiple IL IN subtypes.
Transgenic mouse lines labelling various IN populations with optogenetic tools could be used to
determine the specifics subtypes involved. Previous research may indicate which IN subtypes in
the IL are likely to express CaV2.2. A plethora of studies have described laminar organization and
cell diversity in the mPFC and neocortex at large. It is possible these properties are conserved in
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the IL, despite cytoarchitecture and CaV-dependent neurotransmitter release have not been
extensively studied in this region. Cruikshank and colleagues (2012) report that INs in L1 of the
PFC are exclusively GABAergic, but heterogeneous otherwise. Several IN subtypes located in L1
have been shown to inhibit P-cells in L2/3. These include neurogliaform cells (Cauli, Zhou,
Tricoire, Toussay, & Staiger, 2014) and horizontal cells (Gabbott, 2016), which form inhibitory
synapses onto P-cell dendrites. It has been demonstrated that horizontal cells in express N-type
calcium channels that are involved in inhibitory feedback circuits (Liu, Hirano, Sun, Brecha, &
Barnes, 2013). These findings were from horizontal cells which innervate photoreceptors, thus
further studies would need to be done to confirm horizontal cells in the IL also express these
properties. More directly associated with CaV2.2 expression in the mPFC, CCK+INs are addressed
in their respective section of this discussion.
Previous research may also indicate which IN subtype in the IL are not likely to express
CaV2.2. GABA release from neurogliaform cells in L1 (Allene et al., 2015) may be facilitated by
L-type CaVs, as this has been shown for their hippocampal analogues (Li et al., 2014). Martinotti
cells, whose soma are distributed in the IL layers which contain P-cells, have long GABAergic
projections which synapse onto P-cell dendrites in L1 (Allene et al., 2015; Cauli et al., 2014).
Martinotti cells have been shown to express L-type CaVs (Wang et al., 2004). GABA release from
PV+BCs, located in the same layers as Martinotti cells and P-cells, is likely facilitated by P/Qtype CaVs (Bartos & Elgueta, 2012). As these three IN subtypes have been shown to express nonN-type channels in other brain regions, they may still release GABA onto L2/3 P-cells after CaV2.2
block. Accordingly, it is possible the CTX condition IPSCs we recorded were due to GABA release
from PV+BCs, Martinotti cells, and neurogliaform cells.
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Localization of CCK+INs in the IL
Fluorescence experiments in our triple transgenic mouse line (CCK-Dlx5/6-tdT) reveal
CCK+IN expression throughout the mPFC, with variability across layers (Figure 18 - left).
Perisomatic inhibitory cells, CCK+BCs and PV+BCs, have been described in the superficial and
deep layers (L2/3-L6) of the mouse IL, PL, and dorsal peduncular area (DP) (Whissell et al., 2015).
CCK+BCs are reported to be the most numerous type of IN in the mPFC, and are significantly
more prevalent than PV+BCs in the IL and DP (Whissell et al., 2015). Our fluorescence images
appear to display similar patterns of pervasive CCK+IN expression in L2/3 and L5, as most cells
appear morphologically to be innervated by the neuronal processes of CCK+INs. Innervations by
CCK+INs in the mPFC are vital for regulating excitatory output; dysfunction in this system has
been linked to the pathogenesis of anxiety disorders (Bachus, Hyde, Herman, Egan, & Kleinman,
1997). Interestingly, we observe the presence of CCK+INs in what laminarly appears to be L1.
This expression pattern has not been specifically reported in the mouse IL before. While CCK+INs
have been shown to be present in L1 of the developing mouse neocortex, CCK mRNA was the
least abundant compared to other neuropeptide markers like calbindin and neuropeptide-Y (J Ma
et al., 2014). Via SYTO-13 labelling, the number of cells located in L1 is relatively low compared
to deeper layers. It has been reported that cells in L1 of the PFC are exclusively GABAergic INs
(Cruikshank et al., 2012). Only a fraction express GABAergic CCK in our composite image
(Figure 18 - right), which may be reflective of the low CCK mRNA content described by J Ma
and colleagues (2014).
L1 CCK+INs likely possess different intrinsic properties and target different cell
populations compared to CCK+INs in L2/3 and L5. As P-cell somas are located in L2/3 and L5
while their dendrites are located in L1 (Riga et al., 2014), L1 CCK+INs may be involved in
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dendritic inhibition rather than perisomatic inhibition. Accordingly, the synaptic properties of L1
CCK+INs may be more similar to neurogliaform, horizontal, and/or Martinotti cells than
CCK+BCs. It appears the web-like GABAergic CCK+ expression patterns of the deep IL layers
are also present in L1, though to a much lesser extent. This could be due to there being a lower
number CCK+INs present in L1, but the inhibition patterns of these cells could also be different.
Morphological studies like biocytin stainings could be used to determine the neuroanatomical
differences between L1 and L2/3 and L5 CCK+INs. The extensive GABAergic CCK+IN
expression we observed in confocal images from our CCK-Dlx5/6-tdT mouse model are a
promising sign for their potential extensive regulatory role on P-cell output in the circuits related
to fear extinction.

CaV2.2 Block does not Significantly Affect GABA release in CCK+IN/P-cell Synapses in the IL
Note: While our optogenetic mouse model (CCK-Dlx5/6-ReaChR) labels all GABAergic
CCK+INs, optogenetic stimulation likely evokes GABA release primarily from CCK+BCs in L2/3.
CCK+BCs are involved in perisomatic inhibition networks with local P-cells (Eggan et al., 2010;
Freund & Katona, 2007) and are more numerous than non-basket cell CCK+INs (Bachus et al.,
1997; J Ma et al., 2014). However, contribution of non-basket cell CCK+INs (possibly in L1)
cannot be ruled out, so results must be applied to the entire population of CCK+INs in the IL.
Contrary to our findings regarding CCK+INs in the BLA (CHAPTER 1), CCK+INs in the
IL did not display CaV2.2-dependent neurotransmitter release properties. Accordingly, CCK+INs
may differ in their CaV2.2 expression/function across brain regions. While GABA release from
hippocampal CCK+INs is entirely CaV2.2-dependent (Szabo et al., 2014), it may be partially
CaV2.2-dependent in the BLA (CHAPTER 1), and not statistically significantly CaV2.2-dependent
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in the IL. However, the lack of CaV2.2-dependent GABA release may not apply to every CCK+IN
in the IL. In two of our recordings, we observed moderate IPSC peak amplitude decreases (47%
and 49%) following CaV2.2 blockade. It could be that in these two cells, selected randomly from
L2/3 of the IL, GABA release was partially CaV2.2-dependent. However, in the cumulative
population of CCK+INs we performed pharmacological recordings in, we did not observe
statistically significant CaV2.2-dependent GABA release.
In addition to differential CaV2.2 expression, variations in CaV2.2-dependent GABA
release could be the result of differential CaV2.2 modulation across CCK+IN subtypes. In several
recordings, we observed an initial decrease in IPSC peak amplitude after CTX addition similar to
the time-course plots from Figures 13 and 16. However, this initial decrease was temporary; after
approximately twenty minutes IPSC peak amplitudes began to return to control condition values.
It is possible a compensatory mechanism was responsible for this observation. The presynaptic
CCK+IN terminal may have compensated for the CaV2.2 blockade, or the P-cell membrane may
have compensated for the decreased GABA binding. Inchauspe and colleagues (2004) report
functional compensation between CaV subtypes: N-type channels compensated for the absence of
P/Q-type channels and evoked synaptic currents at the Calyx of Held. Given P/Q-type channels
contribute to the maintenance of neurotransmission by providing additional faciliatory drive
(Inchauspe, 2004), it is theoretically possible they could compensate for N-type calcium channel
block if co-expressed in presynaptic terminals. If present in CCK+IN terminals, this compensatory
mechanism could lead to much smaller decreases in IPSC peak amplitude following CaV2.2 block
when compared to control conditions. In addition to functional compensation by other CaV
subtypes, CTX may modulate CaV2.2 differently in the CCK+INs of the IL compared to those in
the HPC or BLA. While CTX is generally considered an irreversible blocker, N-type calcium
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current recovery was observable under certain conditions, like in the absence of divalent cations
(Liang & Elmslie, 2002). It is unlikely we would observe this in the IL and not the BLA however,
as our brain slice preparation and internal and external solutions remained consistent.
Comparisons between our two-point segment plots in Figures 16 and 18 allow for more
specific conclusions to be made regarding CaV2.2-dependent neurotransmission. The statistically
significant decrease (mean = 46%) in neurotransmitter release from GABAergic INs following
CaV2.2 block is not facilitated by CCK+INs. We observed transmitter release from CCK+INs did
not significantly change (average 9% decrease) following CaV2.2 block. Speculation as to what
presynaptic GABA release is blocked by CTX includes horizontal cells and non-compensatory
CCK+INs. Overall, there are many possible reasons as to why we did not see statistically
significant changes to IPSC peak amplitude with CTX in CCK+IN/P-cell synapses. Regardless of
the underlying mechanism(s), our observations were reproducible. A likely and concise conclusion
is that in the IL, CaV2.2 does not play a critical role in GABA release from presynaptic CCK+INs.

Pyramidal Cell Spiking is not Significantly Modulated by CaV2.2 in the IL
Under control, CTX, and CdCl2 conditions, we observed ‘initial burst’ patterns from L2/3
P-cells in the IL. Initial bursting occurs when a neuron responds with a significantly greater spike
frequency upon initial current injection, before slowing to a steady-state pattern. Initial bursting is
caused by a series of ‘direct resets’, wherein the cell almost immediately fires from the membrane
potential at which its previous spike ended (Gerstner, Kistler, Naud, & Paninski, 2014). We
observed two direct resets under control and CTX conditions and four under CdCl2. Steady-state
patterns are the result of ‘detour resets,’ which occur when a neuron makes a ‘detour’ into the
region of negative membrane potential (hyperpolarizes) at the beginning of the spike interval
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(Schwalger & Lindner, 2013). Detour resets comprise the entirety of the steady-state phase, which
can be categorized by the patterns produced by inter-spike intervals (ISIs). Under control and CTX
conditions, we observe ‘regular-spiking’ firing patterns (equal ISIs), which are also referred to as
normal, tonic, non-adapting, or non-accommodating. Similar patterns have been previously
reported from P-cells in the IL (Ferreira et al., 2015), the mPFC (Van Aerde & Feldmeyer, 2015),
and the BLA (Rainnie et al., 1993). Under CdCl2 conditions, we observed what appear to be
gradually increasing ISIs, indicative of an adapting or accommodating firing pattern (Gerstner et
al., 2014). Though there are multiple ways to classify firing patterns, the intrinsic cellular
properties producing these patterns are consistent regardless of naming scheme.
There was a distinct change in firing pattern when CdCl2 was applied to P-cells in L2/3 of
the IL. The ISI decreased dramatically from CTX and control patterns, and the direct reset phase
lasted far longer. CdCl2 acts as a calcium channel antagonist, blocking all CaVs (Gadbut, Cash,
Noble, Radice, & Weyhenmeyer, 1991). Thus, the changes we observe from CTX to CdCl2
conditions are due to a combination of P/Q-, L-, T-, and R-type blockade. CaVs allow for prolonged
calcium conductance during each spike, which produces long-duration action potentials in P-cells
when compared to faster spiking interneurons (Rainnie et al., 1993). When CaVs are blocked, it is
likely that calcium entry is no longer prolonged, and thus action potential duration shortens. Along
similar lines, calcium channel modulation has been shown to promote burst firing patterns from
regular firing neurons (Friedman & Gutnick, 1989; S. Rudolph, Hull, & Regehr, 2015). These
concepts are reflected in our experimental design; as we blocked CaVs, we saw greater firing
frequency (< 1 Hz with CTX, > 4 Hz with CdCl2) and an upregulation of bursting. Overall, we can
make specific conclusions only for the control and CaV2.2 blockade conditions, as CdCl2 is not a
specific antagonist like CTX (Gadbut et al., 1991). The lack of statistically significant changes to

99

firing properties we observed following CTX addition indicate that CaV2.2 is not an integral
somatic modifier of P-cell intrinsic firing properties. CaV2.2 in the presynaptic terminal of INs has
a far more important regulatory role over P-cell activity, therefore is likely the more appropriate
pharmacological target for regulating anxiety-related neuronal output.

Additional Considerations for Future Research
The infralimbic cortex, as well as the larger medial prefrontal cortex, present many
opportunities for novel circuit-level functional studies of CaVs. Having observed a robust decrease
in IPSC peak amplitude in GABAergic IN/P-cell synapses following CaV2.2 block, further
investigations of presynaptic inhibition at the level of P-cell dendrites are warranted. Given the
average IPSC peak amplitude decrease was 46%, there are likely other CaV subtypes which
facilitate the remaining release of GABA. Emulating our previous recordings, the L-type blocker
Nimodipine could be introduced to the bath following CaV2.2 block. Martinotti and neurogliaform
cells express L-type channels (Li et al., 2014; Y. Wang et al., 2004), so we predict IPSC peak
amplitude would further decrease. If IPSCs are not fully eliminated by N- and L-type blockade,
ω-Agatoxin IVA could be added to the bath perfusion to block P/Q-type channels, which are
expressed in PV+BCs (Bartos & Elgueta, 2012; Freund & Katona, 2007; Zamponi & Currie, 2013).
By altering the layer of the IL in which we recorded and/or stimulated, many additional circuits
could be studied. For example, simulating L1 and recording from L5 would allow for comparisons
of dendritic inhibition strength in deep L5 P-cells and superficial L2/3 P-cells. It may be that deeper
IL-BLA connections are not as robustly regulated by CaV2.2, in which case other receptors may
be better targets for reducing inhibition of fear extinction.
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As the PL and IL have been shown to influence distinct fear and anxiety-related processes
(Sierra-Mercado et al., 2011), it stands to reason that there could be circuit-level differences
between the two mPFC areas. It has been demonstrated that L5 neurons differ morphologically
based on projection target; the PL and IL differ greatly in this regard (Ferreira et al., 2015).
Irrespective of established cellular differences, functional studies must be run to confirm if
morphologically distinctive cells express unique CaVs and process presynaptic inhibition
differently. In a future experiment, we could replicate our IL recordings to test if CaV2.2 plays a
significant role in neurotransmitter release in the PL, focusing on cell populations with known
synaptic and/or intrinsic differences. Our goal would be to describe if and how CaV2.2
differentially regulates two distinct mPFC regions involved in fear expression and extinction.
Investigations into the role of eCB-dependent and independent CB1 modulation of CaV2.2
could be performed on dendritic and perisomatic inhibitory networks in L2/3 of the IL. CB1
receptor signaling within the mPFC has been shown to potentiate emotional associative learning
through inputs from the BLA (Laviolette & Grace, 2006). However, Laviolette and Grace (2006)
performed extracellular recordings so cell-specific effects were not observable; an entry point from
which we could make novel contributions regarding CaVs. Additionally, CB1 is known to be
expressed in the CCK+INs in the PFC which also express CaV2.2 (Marsicano & Lutz, 1999).
Combined, there are many opportunities to study the relationship between CB1/CaV2.2 in the
infralimbic cortex.
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OVERALL CONCLUSIONS
By investigating the regulation of excitatory output from the BLA, we are interested in
determining new cell-specific targets to mitigate anxiety. Before this is possible, the basic cellular
and molecular mechanisms underlying the relationship between INs and P-cells must be
understood. CaV2.2 has been shown to modulate neurotransmitter release from CCK+INs in the
hippocampus, but its role in the BLA had not been functionally described. With our novel triple
transgenic mouse model, we used optogenetics tools to isolate CCK+IN/P-cell synapses for
functional studies. We found that GABA release from CCK+INs was modulated by CaV2.2 in the
BLA as hypothesized. But, this modulation was only partial. The average peak amplitude of
inhibitory postsynaptic currents was roughly halved following CaV2.2 blockade, whereas studies
of CCK+INs in the HPC would suggest total elimination of current. Our data show that while cell
circuitry may be conserved, CaV2.2 differentially regulates neurotransmitter release from
CCK+INs in the BLA and HPC. We present a challenge to the theory that CaV2.2 is the only CaV
involved in regulating neurotransmitter release from CCK+INs. As CaVs are vital in regulating
neuronal activity, extensive and comprehensive investigations are warranted to uncover more
details as to their role in GABA release from INs in the BLA.
CCK+IN terminals in the BLA almost uniformly express type-1 cannabinoid receptor.
Upon activation by cannabinoids, these receptors are believed to suppress inhibitory
neurotransmitter release and disinhibit P-cells, thus profoundly impacting amygdalar output. The
functional studies required to confirm these predictions were not yet published upon the start of
our research. Beginning with immunofluorescence experiments, we found comparable
colocalization of CB1 and GABAergic CCK expression in the BLA and HPC. Our initial
electrophysiology data suggests that CB1 is involved in both phasic and tonic inhibition of

102

neurotransmitter release from CCK+IN in the BLA. CB1-agonism lead to a decrease in IPSC peak
amplitude, as CB1 inhibits calcium entry though CaVs. Contrarily, CB1-antagonism lead to an
increase in IPSC peak amplitude, as tonic levels of CB1-mediated inhibition of CaVs were
eliminated. A paper published by Rovira-Esteban and colleagues (2017) comprehensively
described the modulation of CCK+IN/P-cell synapses in the BLA by CB1, thus we discontinued
further recordings. Our hypothesis and preliminary data suggest reproducibility of the findings
presented by Rovira-Esteban and colleagues (2017). Ultimately, CB1-containing CCK+INs may
control anxiety at the level of the amygdala and are potential targets for regulating anxiety-related
neuronal output.
Anxiety disorders are often associated with the inability to extinguish fearful or traumatic
memories, a process which in mice is thought to be facilitated by the infralimbic cortex and its
connections to the BLA. The IL is a promising target for anxiety research, as CaV physiology is
relatively understudied despite proposed functional significance. We found that CaV2.2 was not an
integral modulator of P-cell intrinsic firing properties, as CTX had negligible effects on firing
pattern and spike frequency. CaV2.2 displayed a far more significant regulatory role over P-cell
activity in presynaptic INs, which are likely a more appropriate pharmacological target for
regulated neuronal output involved in the extinction of conditioned fear. Our initial
electrophysiology experiments suggest that neurotransmitter release from GABAergic inputs in
L1 of the IL onto P-cells in L2/3 is partially CaV2.2-dependent, similar to our observations in the
BLA. However, the approximate halving of IPSC peak amplitude is not facilitated by CCK+INs,
as our data show neurotransmitter release from these INs is not significantly modulated by CaV2.2.
Overall, our experiments lay groundwork for future functional studies on the role of CaVs
in anxiety-related circuits. We demonstrate that although CCK+IN/P-cell synapses are found in

103

the HPC, BLA, and mPFC, they are differentially regulated by CaV2.2. Therefore, novel
pharmacological treatments for anxiety that target CaV2.2 should consider region-specific effects.
CaV2.2 block likely has therapeutic value in certain neuronal circuits and brain regions, but no
value or even detrimental effects on others. For example, anxiety-related brain activity may be
suppressed in the HPC while simultaneously upregulated in the BLA. Differential effects may be
seen within the mPFC, as upregulation of P-cell activity could facilitate fear-extinction in the IL,
but perpetuate fear expression in the PL. Accordingly, more information must be revealed about
the role of CaV2.2 in anxiety-related neuronal circuits to ensure the safety and efficacy of
developing treatments for anxiety disorders.
As it pertains to the data presented within these chapters, future research should
comprehensively describe the role of each CaV subtype involved in CCK+IN/P-cell synapses in
the BLA and IL. By blocking CaV subtypes in sequential order, we could fully eliminate IPSCs
and determine which are responsible for the remaining IPSC peak amplitude observed in
CHAPTER 1 and CHAPTER 3. Pharmacological agents would need to include Nimodipine (Ltype blocker), ω-Agatoxin IVA (P/Q-type blocker), and SNX 482 (R-type blocker). Given the
discrepancies we observed in CCK+INs across brain regions, it is reasonable to propose
investigations into CaVs in CCK+INs in additional limbic structures like the periaqueductal grey,
anterior cingulate, and central amygdala. On a larger scale, our mouse models serve as a tool for
potential studies on the anatomical, intrinsic, synaptic, and behavioral properties of CCK+INs
throughout the brain.
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